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ABSTRACT
O2 ACTIVATION AND ALLOSTERIC Zn(II) BINDING ON HIF-PROLYL
HYDROXYLASE-2 (PHD2)
SEPTEMBER 2013
SERAP PEKTAS, B.S., CUMHURIYET UNIVERSITY
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by Professor Michael J. Knapp
Oxygen homeostasis is essential to the life of aerobes, which is regulated in
humans by Hypoxia Inducible Factor-1α (HIF-1α). Under hypoxic conditions, HIF-1α
transactivates over a hundred genes related angiogenesis, erythropoiesis, etc. HIF-1α
level and function is regulated by four HIF hydroxylase enzymes: three isoforms of
prolyl hydroxylase domain (PHD1, PHD2 and PHD3) and factor inhibiting HIF-1α
(FIH). PHD2 is the focus of this research. PHD2 is a non-heme Fe(II) 2-oxoglutarate
dependent dioxygenase, which controls HIF-1α levels by hydroxylating two proline
residues within the ODD domain of HIF-1α, then the hydroxylated prolines are
recognized by pVHL, which targets HIF-1α for proteasomal degradation. Under hypoxic
conditions PHD2 cannot hydroxylate HIF-1α and its level rises in cells. The aims of this
research include understanding how PHD2 chooses its substrate, how the O2 activation
occurs, and how certain transition metals inhibit PHD2.
Our results revealed that electrostatics play a role in substrate selectivity of PHD2
by provoking a change in the opening and closing rate of β2β3 loop for NODD and
CODD substrates. Mutational studies of second coordination sphere residues combined
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with kinetic studies indicated that decarboxylation of 2OG is the slow step in the
chemical mechanism. The removal of a hydrogen-bond by the Thr387àAla mutation
revealed a rate 15 times faster than WT-PHD2 by making O2 a better nucleophile. Our
results indicate that this hydrogen bonding is essential for proper O2 activation.
Previous reports show that certain metals increase HIF-1α levels by inhibiting
PHD2. However there are conflicts about how this inhibition occurs, either through
metal replacement from the active site or metals binding to a different site causing
inhibition.

Our competitive and non-competitive kinetic assays showed different

inhibition profiles. Under competitive conditions Zn2+, Co2+, Mn2+, and Cu2+ can bind to
the enzyme active site and lead to inhibition but under non-competitive conditions Zn2+,
Co2+, and Mn2+ partially inhibit PHD2 suggesting that these metals cannot displace the
Fe2+ from the active site. XAS experiments with Zn2+ and Fe3+ indicate that Zn2+ binds to
the surface of PHD2 in a six-coordinate manner composed of two Cys201, 208, His205,
Tyr197 and two water ligands.

	
  

vii	
  

TABLE OF CONTENTS
Page
ACKNOWLEDGMENTS .................................................................................................. v
ABSTRACT....................................................................................................................... vi
LIST OF TABLES ............................................................................................................ xii
LIST OF FIGURES ......................................................................................................... xiii
LIST OF SCHEMES ..................................................................................................... xviii
CHAPTER
I. OXYGEN SENSING ...................................................................................................... 1
1.1
1.2
1.3
1.4
1.5
1.6

Introduction ............................................................................................................ 1
Hypoxia inducible factor (HIF) .............................................................................. 1
HIF-α hydroxylases................................................................................................ 2
HIF Prolyl hydroxylase (PHD2) ............................................................................ 3
Proposed chemical mechanism for HIF hydroxylases ........................................... 5
Materials and methods ........................................................................................... 6

1.6.1 PHD2 mutations .............................................................................................. 6
1.6.1.1

Reagents and protocol ............................................................................ 8

1.6.2 WT-PHD2 and its variants purification ........................................................... 8
1.6.3 The extinction coefficient of PHD2............................................................... 12
1.6.4 Determination of the molecular weight of purified WT-PHD2
and its mutants by mass spectrometer ............................................................ 14
1.6.5 Purification of NODD peptide....................................................................... 17
1.6.6 Mass of purified NODD determined by MALDI .......................................... 18
1.6.7 Initial rate determination of PHD2 and its variants ....................................... 19
1.6.8 Global hydrogen deuterium exchange experiments ...................................... 21
1.7 Bibliography ......................................................................................................... 24
II. SUBSTRATE SELECTIVITY OF PHD2 ................................................................... 27
2.1 Introduction .......................................................................................................... 27
2.2 Experimental Procedures...................................................................................... 32
2.2.1 Materials ........................................................................................................ 32

	
  

viii	
  

2.2.2 Protein expression and purification ............................................................... 33
2.2.3 Steady-state kinetic assays ............................................................................. 33
2.2.4 Global hydrogen deuterium exchange (HDX) kinetics of PHD2 .................. 34
2.3 Results .................................................................................................................. 35
2.3.1 PHD2 shows a preference for CODD over NODD in the presence of both
substrates ....................................................................................................... 35
2.3.2 Columbic forces are essential in substrate preference of PHD2 ................... 36
2.3.3 NODD and CODD bind equivalently to PHD2............................................. 38
2.4 Discussion ............................................................................................................ 41
2.5 Bibliography ......................................................................................................... 46
III. THR387 IS THE KEY RESIDUE IN O2 ACTIVATION OF PHD2 ........................... 50
3.1 Introduction .......................................................................................................... 50
3.2 Materials and Methods ......................................................................................... 53
3.2.1
3.2.2
3.2.3
3.2.4
3.2.5
3.2.6

Materials ........................................................................................................ 53
Protein expression and purification ............................................................... 53
Steady state kinetic assays ............................................................................. 54
Intrinsic fluorescence quenching ................................................................... 55
Kinetic solvent isotope effect experiments (KSIE) ....................................... 55
Determination of KM(O2) ................................................................................ 56

3.3 Results .................................................................................................................. 56
3.3.1
3.3.2
3.3.3
3.3.4
3.3.5
3.3.6

Steady state kinetics with varied [2OG] ........................................................ 56
Binding constants for 2OG ............................................................................ 59
Steady state kinetics with varied [CODD] .................................................... 60
Kinetic SIE on kcat.......................................................................................... 63
Steady state kinetics with varied [O2]............................................................ 65
Inhibition by added succinate ........................................................................ 67

3.4 Discussion ............................................................................................................ 68
3.5 Bibliography ......................................................................................................... 73
IV. PHD2 HAS A Zn(II) BINDING ALLOSTERIC SITE .............................................. 77
4.1 Introduction .......................................................................................................... 77
4.2 Experimental procedures ...................................................................................... 80
4.2.1 Materials ........................................................................................................ 80
4.2.2 Protein expression and purification ............................................................... 81
4.2.3 Initial rate measurements ............................................................................... 81

	
  

ix	
  

4.2.4 Metal inhibition assays .................................................................................. 81
4.2.5 X-ray Absorption Spectroscopy Sample Preparation .................................... 82
4.3 Results .................................................................................................................. 82
4.3.1 PHD2/Cys201àAla has different inhibition profile with different addition
order of metals ............................................................................................... 82
4.3.2 Addition of second metal does not change KM(CODD) except for
the Co2+, and Zn2+…. .................................................................................... 87
4.3.3 XAS shows that Zn2+ binds to the allosteric site on WT-PHD2 ................... 89
4.4 Discussion ............................................................................................................ 91
4.5 Bibliography ......................................................................................................... 93
V. SECOND COORDINATION SPHERE CONTROLS HIF-1α
HYDROXYLATION ................................................................................................ 96
5.1 Introduction .......................................................................................................... 96
5.2 Materials and methods ......................................................................................... 99
5.2.1 Materials ........................................................................................................ 99
5.2.2 Point mutations .............................................................................................. 99
5.2.3 Purification of WT-PHD2 and its mutants, Asp315àAla, Asp315àGlu,
and Thr325àAla ............................................................................................101
5.2.4 Steady state kinetic assays ........................................................................... 102
5.2.5 Buffer preparation to obtain pH profile ....................................................... 102
5.2.6 Steady state kinetics for determining KM(O2) ............................................... 102
5.2.7 UV-Vis spectroscopy................................................................................... 103
5.3 Results ................................................................................................................ 103
5.3.1 Thr325àAla plays a key role in hydroxylating the CODD
substrate peptide .......................................................................................... 103
5.3.2 Mutations did not alter the protonation state of PHD2 ................................ 106
5.3.3 WT-PHD2 and mutants have similar KM(O2) exception the
Asp315àGlu mutant which showed inhibition at high [O2] ........................ 108
5.3.4 Electron density around the Fe2+ has been altered in Asp315àAla
and Asp315àGlu mutants ............................................................................ 110
5.4 Discussion .......................................................................................................... 111
5.5 Bibliography ....................................................................................................... 114
VI. FUTURE DIRECTIONS ......................................................................................... 117

	
  

x	
  

APPENDICES
A. pGEX-4T-1 VECTOR (FROM GE HEALTHCAR) .............................................. 120
B. AMINO ACID SEQUENCE OF WT-PHD2178-426 THAT WAS USED
IN THIS STUDY ..................................................................................................... 121
C. FORWARD AND REVERSE PRIMER SEQUENCES OF MUTANTS .............. 122
BIBLIOGRAPHY ............................................................................................................123

	
  

xi	
  

LIST OF TABLES
Table

Page

1.1 PCR reaction mixtures. ................................................................................................. 7
1.2 PCR program settings. .................................................................................................. 8
1.2 The extinction coefficients of fluorescent residues. ................................................... 13
1.3 HPLC gradient protocol. ............................................................................................. 17
1.4 HPLC gradient for NODD purification. ..................................................................... 18
2.1 Steady state kinetic constants for PHD2 using CODD or NODD. ............................. 38
2.2 Global amide HDX kinetics of PHD2.a, b.................................................................... 41
3.1 Steady state kinetics of WT-PHD2 and mutants with varied [2OG]. ......................... 59
3.2 Steady state kinetic constants, kcat and kcat/KM of WT-PHD2,
Thr387→Ala and Thr387→Asn for CODD substrate peptide. .................................... 63
3.3 SIE kinetic parameters for PHD2 and its variants. ..................................................... 64
3.4 Steady state kinetics constants kcat(O2) and kcat/KM(O2) for WT-PHD2,
Thr387àAla, and Thr387àAsn. ................................................................................. 66
3.5 WT-PHD2 and Thr387àAla KI(Succinate). ...................................................................... 68
4.1 Steady state kinetic constants in the presence of 50 µM Mn2+, Co2+, Ni2+, or Zn2+
for WT-PHD2 pre incubated with Fe2+ (10 µM), 2OG (100 µM),
ascorbic acid (1 mM). ............................................................................................... 88
	
  
4.2 Selected EXAFS fits for WT-PHD2 and Cys201àAla with Zn2+ and Fe3+
(Done by Carolyn Carr) ............................................................................................ 90
5.1 PCR reaction conditions. .......................................................................................... 100
5.2 The PCR program setting.......................................................................................... 100
5.3 Steady state kinetic parameters of WT-HD2 and mutants for CODD and 2OG. ..... 105
5.4 pKa of WT-PHD2 and its mutants. ........................................................................... 107
5.5 Steady state kinetic parameters of WT-PHD2 and mutants for O2. .......................... 109

	
  

xii	
  

LIST OF FIGURES
Figure

Page

1.1 Domains of HIF-1α and HIF-1β. ................................................................................. 2
1.2 Hypoxia pathway. ......................................................................................................... 5
1.3 pGEX-4T-1 vector plasmid map with PHD2, glutathione S-transferase (GST) tag and
thrombin cleavage site. ............................................................................................... 7
1.4 SDS page showing the purity of purified PHD2......................................................... 10
1.5 Masses of WT-PHD2, Thr387àAla, Thr387àAsn, Cys201àAla, Asp315àAla,
Asp315àGlu and Thr325àAla by QSTAR-TOF mass spectrometer........................ 17
1.6 Mass of purified NODD determined by MALDI. ...................................................... 19
1.7 MALDI spectrum showing the formation of hydroxylated peptide by time. Black
spectrum is CODD peptide at 30 seconds of the reaction. Gray spectrum is CODD
peptide at 2.5 minutes of the reaction. ...................................................................... 20
1.8 The initial rate of CODD hydroxylation. .................................................................... 20
1.9 Determination of deuterium incorporation to PHD2 with time. QStarXL is used to
determine mass change in PHD2 with time. Black mass spectrum is apo PHD2 (5
µM) at time 0 and gray mass spectrum is apo PHD2 (5 µM) at 60 minutes. Mass of
PHD2 was determined by Analyst QS 1.1 software and predicted charge states were
shown. ....................................................................................................................... 22
1.10 Closer view of the mass spectrum in figure 1.9, showing the mass change due to
deuterium incorporation to the protein for +34 and +33 charge state at time 0 (black)
and 60 minutes (gray). X is impurities..................................................................... 23
2.1 Structure of (Mn+NOG)PHD2 bound to CODD [30] showing the β2β3 loop (red) and
CODD (cyan) PDB IDs: 3HQR and 2G19 ............................................................... 31
2.2 Substrate selectivity of PHD2 under competitive condition. PHD2 (1 µM), 2OG (100
µM), ODD (2-18 µM; 20 mM total), (NH4)2Fe(SO4)2 (10 µM) and ascorbic acid (1
mM) in 50 mM HEPES pH 7.00 at 37 oC. (CODD (o), NODD (●)). ..................... 36
	
  
	
  
	
  

	
  

xiii	
  

2.3 The effect of 100 mM NaCl on the kinetics of ODD hydroxylation by PHD2. PHD2
was incubated with saturating 2OG (100 µM), (NH4)2Fe(SO4)2 (10 µM), and
ascorbic acid (1 mM), but varied ODD (0 – 50 mM) in 50 mM HEPES pH 7.00 at
37.0 oC. CODD, (o) no NaCl added and (●) 100 mM NaCl added. NODD, (Δ) no
NaCl added and (▲) 100 mM NaCl added. ............................................................. 37
2.4 Global amide HDX kinetics of PHD2. (■) PHD2 (5 µM) in 10 mM NH4OAc pH 7.0,
(○) PHD2 (5 µM), MnSO4 (20 µM), and 2OG (100 µM) (●) PHD2 (5 µM), MnSO4
(20 µM) 2OG (100 µM), and NODD (50 µM), (▲) PHD2 (5 µM), MnSO4 (20 µM),
2OG (100 µM), and CODD (50 µM). Inset: low concentration conditions, [NODD]
or [CODD] = 20 mM. ............................................................................................... 39
3.1 PHD2 active site (PDB ID: 3OUJ). Waters (red sphere), distances (Å)..................... 53
3.2 Thr387àAla shows inhibition at high 2OG concentration. Reaction mixture includes,
Thr387àAla, (0.3 µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1 mM), 2OG (11000 µM), and CODD (10 µM) in 50 mM HEPES pH 7.00, 37°C, ambient [O2](217
µM). .......................................................................................................................... 58
3.3 Determination of steady state kinetic constants kcat /KM(2OG) for WT-PHD2 and
Thr387àAsn. Graph A is WT-PHD2 and graph B is Thr387àAsn. Reaction mixture
includes, WT-PHD2 or Thr387àAsn, (1 µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic
acid (1 mM), 2OG (1-3000 µM), and CODD (10 µM) in 50 mM HEPES pH 7.00,
37°C, ambient [O2](217 µM). ................................................................................... 59
3.4 Determination of KD(2OG) for WT-PHD2, Thr387àAla and Thr387àAsn upon
intrinsic fluorescence quenching of tryptophan upon binding of 2OG to the enzyme
active site. Closed circles WT-PHD2 (1.1 µM), open circles Thr387àAla (1 µM ),
triangles Thr387àAsn (1.1 µM), each with MnSO4 (20 µM) in 50 mM HEPES pH
7.00 titrated with 2OG (500 µM). ............................................................................. 60
3.5 Determination of kinetic constants kcat/KM(CODD) for WT-PHD2 and Thr387àAsn.
Triangles WT-PHD2 and circles are Thr87àAsn. Reactions include, WT-PHD2 (1
µM) or Thr387àAsn (2 µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1 mM), 2OG
(100 µM), and CODD (2-40 µM) in 50 mM HEPES pH 7.00, 37°C, ambient
[O2](217 µM). ........................................................................................................... 62
3.6 Substrate inhibition for Thr387àAla at high CODD concentration. Reaction mixture
included Thr387àAla (0.2 µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1 mM),
2OG (100 µM), and CODD (2-50 µM) in 50 mM HEPES pH 7.00, 37°C, ambient
[O2](217 µM). Insert is the steady state kinetics between 2 µM to 50 µM
CODD. ...................................................................................................................... 62
	
  
	
  
	
  

	
  

xiv	
  

3.7 Solvent isotope effect on WT-PHD2, Thr387àAla, and Thr387àAsn. WT-PHD2 in
D2O buffer (▲), WT-PHD2 in H2O buffer (Δ); Thr387àAsn in D2O buffer (■),
Thr387àAsn in H2O (☐). Thr387àAla in D2O buffer (●); H2O buffer (○). Reactions
include, WT-PHD2 (1 µM), Thr387àAla (1 µM), or Thr387àAsn (0.3 µM),
(NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1 mM), 2OG (100 µM), and CODD (10
µM) in 50 mM HEPES pH 7.00 or pD 7.00, 37°C, ambient [O2](217 µM). ............ 64
3.8 Steady state kinetics constants kcat(O2) and kcat/KM(O2) for WT-PHD2 and Thr387àAsn.
Reaction mixture includes, WT-PHD2 (1 µM) or Thr387àAsn (2 µM),
(NH4)2Fe(SO4)2 (10 µM), 2OG (100 µM), CODD (10 µM), and ascorbic acid (1
mM) in 50 mM HEPES pH 7.00. Open circles are WT-PHD2 and the closed circles
are Thr387àAsn. ....................................................................................................... 65
3.9 Steady state kinetics constants kcat (O2) and kcat/KM (O2) for Thr387àAla. Reaction
mixture includes, Thr387àAla (0.2 µM), (NH4)2Fe(SO4)2 (10 µM), 2OG (100 µM),
CODD (10 µM), and ascorbic acid (1 mM) in 50 mM HEPES pH 7.00. Insert,
steady state kinetics of Thr387àAla between 6 µM to 760 µM O2. ......................... 66
3.10 Inhibition of WT-PHD2 and Thr387àAla. Upper panel is WT-PHD2 and the lower
panel is Thr387àAla. Reaction includes, ascorbic acid (1 mM), (NH4)2Fe(SO4)2 (10
µM), PHD2 (0.15-1 µM), 2OG (2-100 µM) and succinic acid (0-1 mM) in an air
saturated 50 mM HEPES pH 7.00 at 37 oC. ............................................................. 67
4.1 A) Allosteric site showing the Zn2+ binding residues, H2O (red sphere) PDB ID:
2G19. B) PHD2 active site showing the Fe2+ and coordinating residues, H2O (red
sphere) PDB ID: 3OUJ. ............................................................................................ 80
4.2 Inhibition of WT-PHD2 from concentration of 10-200 µM M2+ (M2+ = Mn2+, Co2+,
Ni2+, Cu2+, Zn2+). Panel A, the metals were added at the same time with cofactor
Fe2+ and co-substrate 2OG. Panel B, second metal MSO4 added after pre incubated
WT-PHD2 with Fe2+. Reactions performed with WT-PHD2 (1 µM), 2OG (100
µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1mM), M(SO4) (0-200 µM) and ODD
(20 µM) in 50 mM HEPES pH 7.00 at 37 oC. .......................................................... 84
4.3 Inhibition of Cys201àAla from concentration of 10-200 µM M2+ (M2+ = Mn2+, Co2+,
Ni2+, Cu2+, Zn2+). Panel A, the metals were added at the same time with cofactor
Fe2+ and co-substrate 2OG. Panel B, second metal MSO4 added after pre incubated
the Cys201àAla with Fe2+. Reactions performed with WT-PHD2 (1 µM), 2OG (100
µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1mM), M(SO4) (0-200 µM) and
CODD (10 µM) in 50 mM HEPES pH 7.00 at 37 oC. .............................................. 85
4.4 Inhibition of WT-PHD2 by Mn2+, Co2+, Ni2+, and Zn2+ when PHD2 pre incubated
with one of these metals then increasing [Fe2+] from 10 µM to 200 µM. Reactions
performed with WT-PHD2 (1 µM), 2OG (100 µM), MSO4 (10 µM), ascorbic acid
(1mM), (NH4)2Fe(SO4)2 (0-200 µM) and CODD (20 µM) in 50 mM HEPES pH 7.00
at 37 oC...................................................................................................................... 86

	
  

xv	
  

4.5 Inhibition of WT-PHD2 by Mn2+, Co2+, Ni2+, and Zn2+ when (Fe2+)PHD2 incubated
with one of these metals for three hours. Reactions performed with WT-PHD2 (1
µM), 2OG (100 µM), MSO4 (50 µM), ascorbic acid (1mM), (NH4)2Fe(SO4)2 (10
µM) and CODD (20 µM) in 50 mM HEPES pH 7.00 at 37 oC. ............................... 86
4.6 Steady state kinetics for WT-PHD2 pre incubation with Fe2+ (10 µM), 2OG (100 µM)
and 50 µM M2+ (Mn2+, Co2+, Ni2+, or Zn2+). Reactions were performed, 1 µM WTPHD2 pre incubated with Fe2+ (10 µM), 2OG (100 µM), ascorbic acid (1 mM), M2+
(50 µM) and ODD (2-20 µM) in 50 mM HEPES pH 7.00 at 37 oC. ........................ 88
4.7 K-edge XAS spectra of WT-PHD2 with Zn(II) (Done by Carolyn Carr)................... 89
4.8 K-edge XAS spectra of Cys201àAla with Zn2+ (Done by Carolyn Carr) .................. 90
5.1 Active site of PHD2 showing the 2His1Asp facial triad, 2OG and Thr325 residue. PDB
ID: 3OUJ, distances (Å) and Water (red sphere). ..................................................... 98
5.2 Determination of kinetic constants kcat/KM(CODD) for WT-PHD2, Asp315àAla,
Asp315àGlu, and Thr325àAla. Closed squares are WT-PHD2, open triangles are
Asp315àAla, closed triangles are Asp315àGlu, and open circles are Thr325àAla.
Reactions include, WT-PHD2 (1 µM) or mutant (2-10 µM), (NH4)2Fe(SO4)2 (10
µM), ascorbic acid (1 mM), 2OG (100 µM), and CODD (2-20 µM) in 50 mM
HEPES pH 7.00, 37°C, ambient [O2](217 µM). ..................................................... 104
5.3 Determination of kinetic constants kcat/KM(2OG) for WT-PHD2 and, Asp315àAla,
Asp315àGlu, and Thr325àAla. Closed squares are WT-PHD2, open triangles are
Asp315àAla, closed triangles are Asp315àGlu, and open circles are Thr325àAla.
Reactions include, WT-PHD2 (1 µM) or mutant (2-10 µM), (NH4)2Fe(SO4)2 (10
µM), ascorbic acid (1 mM), 2OG (1-50 µM), and CODD (20 µM) in 50 mM HEPES
pH 7.00, 37°C, ambient [O2](217 µM). .................................................................. 105
5.4 pKa of WT-PHD2 and its mutants. Closed squares are WT-PHD2, open triangles are
Asp315àAla, closed triangles are Asp315àGlu, and open circles are Thr325àAla.
Reactions include, WT-PHD2 (1 µM) or mutant (2-10 µM), (NH4)2Fe(SO4)2 (10
µM), ascorbic acid (1 mM), 2OG (100 µM), and CODD (20 µM) in HMP (HEPES +
MES + PIPES) or CHES buffer at ambient [O2], 37 °C. ........................................ 107
5.5 Determination of kinetic constants kcat/KM(O2) for WT-PHD2, Asp315àAla,
Asp315àGlu, and Thr325àAla. Closed squares are WT-PHD2, open triangles are
Asp315àAla, closed triangles are Asp315àGlu, and open circles are Thr325àAla.
Reactions include, WT-PHD2 (1 µM) or mutant (2-10 µM), (NH4)2Fe(SO4)2 (10
µM), ascorbic acid (1 mM), 2OG (100 µM), and CODD (20 µM) in 50 mM HEPES
pH 7.00, 37 °C. ....................................................................................................... 109
	
  
	
  

	
  

xvi	
  

5.6 The UV-visible spectrum of WT-PHD2, Asp315àGlu, and Asp315àAla with Fe2+
2OG. (Fe2+ + 2OG)WT-PHD2, (Fe2+ + 2OG)Asp315àGlu, and (Fe2+ + 2OG)
Asp315àAla. Black line is (Fe2+ + 2OG)WT-PHD2, sample includes 600 µM WTPHD2, 550 µM Fe2+ and 600 µM 2OG. Dark gray line is (Fe2+ + 2OG)Asp315àGlu,
sample includes 600 µM Asp315àGlu, 550 µM Fe2+, and 600 µM 2OG. Light gray
line is (Fe2+ + 2OG)Asp315àAla, samples includes, 350 µM Asp315àGlu, 320 µM
Fe2+, and 350 µM 2OG in 50 mM HEPES 150 mM NaCl pH 7.00. ...................... 111
6.1 A) PHD2 crystal structure without substrate (2G19). B) PHD2 crystal structure with
the substrate (colored purple) (3HQR). (Both structures have the same
orientation). ............................................................................................................. 118
6.2 A view of O2 channel, showing the residues line in front of the channel. Purple stick
representation is CODD. ......................................................................................... 119
	
  

	
  
	
  
	
  

	
  

xvii	
  

LIST OF SCHEMES
Scheme

Page

1.1 The consensus chemical mechanism for 2OG oxygenases........................................... 6
	
  
2.1 Consensus mechanism and ODD sequences............................................................... 28
	
  
3.1 Consensus chemical mechanism of non heme Fe(II), 2OG dependent oxygenases. .. 52
	
  
3.2 Steps in the chemical mechanism of Thr387àAla showing the inhibition
mechanism by 2OG................................................................................................... 71
	
  
3.3 Steps in the chemical mechanism of Thr387àAla showing the inhibition
mechanism by CODD. .............................................................................................. 72
	
  
5.1 Proposed chemical mechanism for PHD2 .................................................................. 97
	
  

	
  

xviii	
  

CHAPTER I

OXYGEN SENSING
1.1

Introduction
Oxygen plays a key role in the energy production of cell. Glycolysis produces 2

adenosine-5’-phosphate molecules (ATP) whereas oxidative phosphorylation of glucose
produces 28 to 34 ATP, making oxygen one of the key molecules in energy metabolism1.
In addition to its role in energy metabolism, oxygen is also involved in other biochemical
reactions making it essential to the life of aerobes. Although it is important, the oxygen
molecule can also be harmful at the same time. Up regulation of oxygen, termed
hyperoxia, causes oxidative cellular damage. Too low oxygen levels, known as hypoxia,
are also dangerous to cells. Under hypoxic conditions cells cannot produce enough ATP
and other oxygen required biochemical reactions do not occur.
Thus, oxygen homeostasis is essential to the life of aerobes. Cells have their own
system to adapt to changes in oxygen levels. In mammals this system known as hypoxia
inducible factor (HIF), a transcription factor which functions as the major regulatory of
oxygen homeostasis2–4.
1.2

Hypoxia inducible factor (HIF)
Hypoxia inducible factor is a transcription factor which activates the expression

of the genes related angiogenesis, erythropoiesis, and ischemia, etc5–7.

HIF is

heterodimer consisting of two subunits, HIF-α and HIF-β. HIF-α is mostly localized in
the cytoplasm and is highly dependent on oxygen levels whereas HIF-β subunit is mostly

	
  

1	
  

localized in the nucleus and is constitutively expressed; its level is independent of oxygen
concentration2. HIF-β, also known as the aryl hydrocarbon nuclear translocator (ARNT),
is involved in transcriptional regulation of other genes. HIF-α has three known isoforms,
HIF-1α, HIF-2α and HIF-3α. Among these isoforms HIF-1α is the most studied. HIF1α contains four domains: basic-helix-loop helix domain (bHLH) important for binding
to the DNA, per-arnt-sim domain (PAS) important for dimerization with HIF-1β subunit,
and the oxygen dependent degradation (ODD) and C-terminal transactivation domains
responsible for its regulatory function (Figure 1.1)2,8.
Under sufficient cellular oxygen concentration, termed normoxia, HIF-1α is degraded
and the transcription of hypoxia related genes does not occur.

HIF-1α stability is

controlled by the HIF-prolyl hydroxylases (PHD1, PHD2, and PHD3 in humans)9,10
which hydroxylate specific proline residues found in the N- and C-terminal O2-dependent
degradation domains of HIF-1α: NODD (Pro402) and CODD (Pro564), leading to
proteasomal degradation of HIF-1α11,12.

Figure 1.1 Domains of HIF-1α and HIF-1β.
1.3

HIF-α hydroxylases
There are four HIF hydroxylase enzymes which hydroxylate HIF-1α, three

isoforms of HIF prolyl hydroxylase domain (PHD1, PHD2, and PHD3) and factor
inhibiting HIF (FIH). PHD’s and FIH follow different pathways in regulation HIF-1α
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(Figure 1.2)13. PHD hydroxylates two proline residues in the ODD domain of HIF-1α
which target HIF for proteasomal degradation3,14. On the other hand, FIH hydroxylates
the Asn308 residue in the CTAD domain of HIF-1α15–17. Asparagine hydroxylation of
HIF-1α does not inhibit translocation to the nucleus, dimerization with HIF-1β subunit,
or binding to DNA but prevents the binding of transcriptional coactivator p300. Without
p300 transcription does not occur15–18.
1.4

HIF Prolyl hydroxylase (PHD2)

HIF prolyl-4-hydroxylase (PHD), is a non heme Fe(II), 2-oxoglutarate (2OG)
dependent oxygenase.

It is an O2 sensor in humans and regulates the level of

transcription factor, HIF-1α, in the cell by hydroxylating specific proline residues on
ODD domain of HIF-1α10,19–21. Involvement of HIF-1α in aerobic/anaerobic metabolism,
angiogenesis, and erythropoiesis makes the PHD2 target for HIF-1α mediated disease22,
23

. PHD has three isoforms PHD1 (HPH3, EGLN2), PHD2 (HPH2, EGLN1) and PHD3

(HPH1, EGLN3)24,25 among these isoforms PHD2 is deemed the major O2 sensor in
humans19,24,26, as suggested by its higher expression level than the other isoforms, thus it
is the main focus of this research. PHD1 is localized in nucleus, PHD2 is mostly
localized in cystoplasm and PHD3 is distributed in both the cystoplasm and nucleus27.
PHD1 and PHD2 can hydroxylate Pro402 and Pro564 whereas PHD3 only hydroxylates
Pro564 but not Pro402 27 hydroxylated prolines then captured by the von Hippel-Lindau
tumor suppressor (pVHL), a part of E3 ubiquitin ligase which targets HIF-1α for
protesomal degradation11,24,28,29.

Hydroxylation of one of these proline residues is

enough for degradation11,12,30. PHD2 N-terminal contains Myeloid Nervy and DEAF-1
(MYND)-type zinc finger domain and C-terminal contains catalytic domain31,32. PHD2
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expressed as only C-terminal catalytic domain due to solubility problem of full length
PHD2. In order for PHD2 function it requires O2, Fe2+, 2OG, and ascorbic acid to keep
the Fe in reduced state. The PHD2 active site is six coordinate, with an Fe2+ cofactor
coordinated in a common His2Asp facial triad and three aquo ligands.
Despite its physiological importance, questions remain about the specifics of
PHD2. One of the questions is, what is the substrate preference of PHD2? And how does
PHD2 choose between the CODD and NODD substrates?

This is important to

understand in order to design effective peptide inhibitors and we addressed this question
using substrate competition assays, electrostatics, and global hydrogen deuterium
exchange experiments (HDX).

Another important question to answer is, how does

substrate binding trigger O2 activation and what is the mechanism O2 activation? This
question remains unknown for all the HIF hydroxylases. We studied O2 activation of
PHD2 by making point mutations of second coordination sphere residues which are
involved in hydrogen bonding to first coordination sphere residues. We used steady state
kinetic assays and kinetic solvent isotope effect experiments (KSIE) to evaluate these
mutations. The third question that remains to be answered is, what is the mechanism of
metal inhibition of PHD2? It is known that certain transition metals inhibit PHD2 but
how do they inhibit the enzyme is unknown. The first possibility is that these metals
inhibit PHD2 by replacing the Fe2+ cofactor within the active site or that these metals
inhibit PHD2 by binding to an allosteric site on the enzyme rather than the active site.
We investigated the mechanism of metal inhibition by performing metal competition
assays and through X-ray absorption spectroscopy.
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Figure 1.2 Hypoxia pathway.
1.5

Proposed chemical mechanism for HIF hydroxylases
HIF hydroxylases have a six coordinate active site. Within the active site, Fe2+ is

coordinated with 2His1Asp facial triad and three water ligands. A consensus chemical
mechanism has been proposed for this family of enzymes in which the activation of
oxygen leads to decarboxylation of 2OG and the hydroxylation of the substrate (Figure
1.3)33,34. According to the consensus mechanism, binding of 2OG displaces two aquo
ligands from the active site33,34. When substrate binds an additional aquo ligand is
released and the coordination geometry of Fe(II) changes from six to five coordinate,
creating a binding site for O235. Upon binding of O2, activated oxygen decarboxylates
2OG, forming a Fe(IV)-oxo intermediate. This Fe(IV)-oxo intermediate hydroxylates the
substrate36,37.
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Scheme 1.1 The consensus chemical mechanism for 2OG oxygenases.
1.6

Materials and methods

1.6.1 PHD2 mutations
Mutation primers were designed using the Quick change primer design program
of Stratagene. Secondary structures (i.e. hairpins) were checked using Integrated DNA
technologies (IDT). Primers were purchased with purity of >85% (using HPLC) through
IDT. PCR reactions were prepared as shown in table 1.1 then the PCR performed using
the program settings in table 1.2.

After the PCR reactions, the 10 µL of each samples

mixed with 2 µL 6X loading dye then run on an agarose gel with 100 volt power. PCR
reactions, which had products were transformed into XL1-Blue cells and DNA
sequencing was performed at GeneWiz. Sequencing primers used were #29 forward 5’-
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GTACCTGGGTTACACGGACCTAC-3’

and

#35

reverse

5’

–

CTCCGCTATCGCTACGTGACTG – 3’.
164 SspI (1)
289 DraII (1)
463 MscI (1)
GST 258..938
647 XmnI (1)
4760 Bsu36I (1)
682 SwaI (1)
4307 SfoI (1)
Thrombin 918..938
4307 NarI (1)
930 BamHI (1)
4307 KasI (1)
936 SacII (1)
4307 BbeI (1)
970 NgoMIV (1)
4172 HpaI (1)
970 NaeI (1)
4116 EcoRV (1)
989 XhoI (1)
3875 Bsp120I (1)
989 AvaI (1)
3875 ApaI (1)
Vector Map
3849 BstEII (1)
4969 bp
3668 MluI (1)

3345 BstAPI (1)
3244 PflMI (1)
2944 DrdI (1)
2638 AlwNI (1)

1294 NcoI (1)
PHD2 939..1682
1423 AccI (1)
1423 BstZ17I (1)
1537 NdeI (1)
1671 AatII (1)
1671 ZraI (1)
1918 PstI (1)
2159 Eam1105I (1)

Figure 1.3 pGEX-4T-1 vector plasmid map with PHD2, glutathione S-transferase (GST)
tag and thrombin cleavage site (GE Healthcare).
Table 1.1 PCR reaction mixtures.
Reagent

Stock concentration

Volume used

ddH2O

84 µL

10X reaction buffer

10 µL

dNTP

1 µL

MgSO4

Final amount

100 mM

1 µL

1 mM

Primer (Sense)

125 ng/µL

1 µL

125 ng

Primer (Anti-sense)

125 ng/µL

1 µL

125 ng

pGEX-4T

100 ng/µL

1µL

100 ng

Vent polymerase
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Table 1.2 PCR program settings.
Step

Temperature (OC)

Time

Denaturing

95

50 seconds

Denaturing

95

50 seconds

Annealing

62-65

50 second

Extension

72

7 minutes

Extension

72

7 minutes

Store

4

Steps shown in bold represents 16 cycles performed.
1.6.1.1 Reagents and protocol
50X TAE buffer (agarose gel running buffer) (1 L)
Tris base

242 g

2M

Acetic acid 57.1 mL
Na2EDTA 37.2 g

2M

Volume adjucted to 1 L with ddH2O.

10 % agarose gel
Agarose 1 g
TAE buffer 100 mL
Heated inside the microwave until completely dissolved.
1.6.2 WT-PHD2 and its variants purification
The cell paste was thawed and suspended in lysis buffer with the ratio of 2 mL
lysis buffer per gram of cell paste. The cell was treated by ultra-sonication until the
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solution became homogenous. After sonication, DNAse was added with the ratio of 0.5
µl DNAse per mL of cell lysate and the solution was incubated for 30 minutes at 4 oC.
Next, the cell lysate was centrifuged for 45 minutes at 12500 rpm to remove cell debris.
The supernatant was then dialyzed with 1X PBS pH 7.40 at 4 oC overnight to equilibrate
with the buffer and pH.

The cell lysate was filtered with 0.45 mm sterile filter to remove any particles.
GSTrap column buffer was adjusted with 1X PBS pH 7.4 buffer then cell lysate was
loaded to the column with 1 mL/min flow rate. After loading the cell lysate to the
GSTrap column, the column was washed with 1X PBS pH 7.4 to remove unbound
proteins. Then GST-PHD2 eluted off the column by elution buffer. The eluted GSTPHD2 was buffer exchanged by dialysis overnight in 1X PBS pH 7.4 at 4 oC for thrombin
cleavage. Following buffer exchange, eluted GST-PHD2 was treated with restriction
grade thrombin to cleave the GST-tag with the ratio of 0.5 unit thrombin per mg of GSTPHD2 for 16 hours at 4 oC. After 16 hours of thrombin treatment, thrombin was removed
by HiTrap-Benzamidine column followed by GST-tag removal by GSTrap column.
Purity of protein was monitored using 10 % SDS page and mass spectrometry was used
to determine the mass of the PHD and its mutants. Later, pure PHD2 was treated with 50
mM EDTA for overnight to remove any metal residue at 4 oC. Then pure PHD2 was
buffer exchanged with 50 mM HEPES pH 7.5 and stored at -20 oC.
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Figure 1.4 SDS page showing the purity of purified PHD2.
1.6.2.1 Reagent protocol
10X PBS buffer preparation (1 L)
80 g NaCl
2 g KCl
14.4 g Na2HPO4
2.4 g KH2PO4
Dissolve in ddH2O and adjust the volume to 1 L. Autoclave and pH adjusted to
7.4.

Lysis buffer
3.1 mg DTT
4.8 mg AEBSF
6 mg lysozyme
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50 mM EDTA
0.1 % TritonX
Dissolve in 1XPBS and adjust the pH to 8.00 by adding 1M NaOH.
Adjust the volume to 20 mL.

Elution buffer
153.6 mg reduced gluthadione
0.5 mL Tris (1M stock)
Dissolve in ddH2O and adjust the pH to 8.00 by adding 1M NaOH.
Adjust the volume to 50 mL.

50 mM HEPES
2.38 mg HEPES
Dissolve in ddH2O and adjust the pH to 7.50 by adding 1M NaOH.
Adjust the volume to 20 mL with ddH2O.

10 % SDS
10 g SDS is dissolved in water and adjust final volume to 100 mL.
Keep in room temperature.

10 % ammonium persulfate (APS)
1 g ammonium persulfate is dissolved in ddH2O.
Final volume is 10 ml.
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Separate into 250 µL/tube.
Freeze in -20°C.

5 % stacking gel for SDS page
0.5 M Tris pH6.8

0.5 mL

33.3% Acrylamide/Bis-acrylamide (19:1)
10% SDS

50 µL

TEMED

5 µL

10% APS

50 µL

ddH2O

2.75 mL

0.6 mL

10 % separation gel for SDS page
1.5 M Tris pH8.8

2.5 mL

33.3% Acrylamide/Bis-acrylamide(19:1)
10% SDS

100 µL

TEMED

5 µL

10% APS

100µL

ddH2O

4.3 mL

3 mL

1.6.3 The extinction coefficient of PHD2
The extinction coefficient of PHD2 was determined based on he method provided
by von Hippel et al. In sample preparation, 20 µM PHD2 was in either 6 M GuHCl or 50
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mM HEPES pH 7.50 buffers.

Absorbance at 280 nm was recorded by UV-Vis

spectrometer and εPHD2 determined using following equations.
A = εlc

(1a)

c = A/εl

(1b)

c(native) = c(6M GuHCl)

(1c)

A(native) / ε(native) = A(6M GuHCl) / ε(6M GuHCl) (1d)
ε(native) = ε(6M GuHCl) × A(native) / A(6M GuHCl)

(1e)

The ε(6M GuHCl) is calculated by using table 1.1 and the following equation.
ε(6M GuHCl) = aε(Trp) + bε(Tyr) + cε(Cys)

(1f)

The a, b, and c letters represent the number of tryptophan, tyrosine, and cysteine residues,
respectively. The extinction coefficient of these residues was provided by von Hippel et
al. and shown on table 1.1.

Table	
  1.2	
  The	
  extinction	
  coefficients	
  of	
  fluorescent	
  residues.	
  
Residue

ε280 nm

Tryptophan a 5690
Tyrosine b 1280
Cysteine c 120
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1.6.4 Determination of the molecular weight of purified WT-PHD2 and its mutants
by mass spectrometer
Molecular weights of WT-PHD2 and its variants were determined by using
QStar-TOF mass spectrometer. 20 µL of 5 µM of each protein sample was run through a
C18 HPLC column with a 10 minute gradient before being injected into QStar-TOF mass
spectrometer. Then the molecular weight was predicted using Analyst QS 1.1 software.
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Figure 1.5 Masses of WT-PHD2, Thr387àAla, Thr387àAsn, Cys201àAla, Asp315àAla,
Asp315àGlu and Thr325àAla by QSTAR-TOF mass spectrometer.

Table 1.3 HPLC gradient protocol.
Time (min)

%B

0

5

1

5

2

5

3

95

5

5

10

5

1.6.5 Purification of NODD peptide
The 20 residue NODD (DALTLLAP402AAGDTIISLDYG) substrate peptide
containing the target Pro402 residue was obtained from EZbiolabs as desalted powder.
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Desalted lyophilized NODD was dissolved in 20 % acetonitrile water solution. Then the
sample was injected into a HPLC column (Higgins Analytical) and purified using the
gradient on table 3. NODD came off of the column between 15-20 minutes of gradient.
Collected NODD sample from HPLC column, lyophilized, and reloaded onto the HPLC
column. This procedure was repeated three times to ensure the purity of peptide. Final
sample was lyophilized and stored in -20 oC.

Table 1.4 HPLC gradient for NODD purification.
Time (min)

%B

0

30

5

31

23

37

25

95

30

95

32

30

37

30

The extinction coefficient of NODD determined as 1280 M-1cm-1 using the equation 1.
The concentration of NODD was measured based on the absorbance at 280 nm on UVVIS spectrometer.
1.6.6 Mass of purified NODD determined by MALDI
In order to determine the mass of NODD peptide MALDI was used. Purified
NODD sample was added to saturated α-cyano-4-hydroxycinnamic acid solution,
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dissolved in 75 % acetonitrile 0.2 % trifluoro acetic acid. Then the sample was spotted
onto a MALDI target plate and analyzed.

Figure 1.6 Mass of purified NODD determined by MALDI.
1.6.7 Initial rate determination of PHD2 and its variants
Initial rates were measured using saturating concentrations of Fe(II) (10 µM), 2OG
(100 µM), ascorbic acid (1 mM), PHD2 or its variants (1-5 µM), and ODD (1- 50 µM) in
50 mM HEPES at 37 oC. Reaction mixture including ascorbic acid, Fe(II), 2OG, and
PHD2 was incubated for 3 minutes then the reactions were initiated by adding the
substrate ODD. Initial rates were obtained by quenching the reactions at varied time
points in MALDI matrix solution. Then the samples were spotted onto a MALDI target
plate an analyzed (Figure 1.7).
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Figure 1.7 MALDI spectrum showing the formation of hydroxylated peptide by time.
Black spectrum is CODD peptide at 30 seconds of the reaction. Gray spectrum is CODD
peptide at 2.5 minutes of the reaction.
	
  

Figure 1.8 The initial rate of CODD hydroxylation.
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1.6.8 Global hydrogen deuterium exchange experiments
Global HDX experiments were measured with an ABI QStar-XL mass
spectrometer. PHD2 (50 µM) was pre-incubated in 10 mM NH4OAc at pH 7.00 on ice
with the cofactor and substrates as indicated: MnSO4 (200 µM), 2OG (1.0 mM), and
CODD or NODD (0 - 500 µM). Mn2+ was used as a structural mimic of Fe2+ in order to
avoid spurious oxidation. The HDX reactions were initiated by diluting 3 µL of PHD2
samples with 27 µL 10 mM NH4OAc (in D2O) pD 7.00 at 25 oC, with aliquots quenched
by injecting onto an HPLC loop at various time points from 15 second to 60 minutes.
Solution pD was determined by adding 0.4 to the pH meter reading (pD = pHmeter + 0.4).
HDX aliquots (20 µL) were injected and buffer exchanged using a C18 HPLC column
with a 0.1 % formic acid (pH 2.5) mobile phase. The HPLC column, injection loop, and
mobile phases were kept in an ice bath to minimize amide back exchange during sample
workup. PHD2 was eluted with a 10 minute gradient, (H2O / CH3CN, 0.1% formic acid),
and was directly sprayed into an ABI QStar-XL for determination of global deuterium
incorporation level. Data was analyzed using Bioanalyst software.
During analysis of HDX samples some amide hydrogens can back exchange with
the HPLC solvent, leading to an apparent loss of deuteration. In order to correct for back
exchange occurring during the LC steps, the deuterium content of PHD2 at each quench
point was corrected through comparison with the mass of a non-deuterated sample (m0)
and the mass of a fully deuterated PHD2 sample (m100). The fully deuterated protein was
prepared by incubation in D2O for a day at 37.0 oC followed by 10 minutes at 70 oC. The
number of exchangeable backbone amides (D) was then calculated by subtracting the
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number of Pro residues (12) and the N-terminus from of the total number of
exchangeable amides on PHD2 (N = 236).
D = N × (mobs – m0)/(m100 – m0)

Figure 1.9 Determination of deuterium incorporation to PHD2 with time. QStarXL is
used to determine mass change in PHD2 with time. Black mass spectrum is apo PHD2 (5
µM) at time 0 and gray mass spectrum is apo PHD2 (5 µM) at 60 minutes. Mass of
PHD2 was determined by Analyst QS 1.1 software and predicted charge states were
shown.
	
  
	
  

	
  

22	
  

Figure 1.10 Closer view of the mass spectrum in figure 1.9, showing the mass change
due to deuterium incorporation to the protein for +34 and +33 charge state at time 0
(black) and 60 minutes (gray). X is impurities.
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

	
  

23	
  

1.7

Bibliography

1.

Rich, P. R. & Rich, P. Keilin Memorial Lecture The molecular machinery of
Keilin ’ s respiratory chain. 1095–1105 (2003).

2.

Wang, G. L., Jiang, B. H., Rue, E. a & Semenza, G. L. Hypoxia-inducible factor 1
is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.
Proceedings of the National Academy of Sciences of the United States of America
92, 5510–4 (1995).

3.

Semenza, G. L. Hydroxylation of HIF-1: oxygen sensing at the molecular level.
Physiology (Bethesda, Md.) 19, 176–82 (2004).

4.

Iyer, N. V. et al. Cellular and developmental control of O2 homeostasis by
hypoxia-inducible factor 1alpha. Genes & Development 12, 149–162 (1998).

5.

Huang, L. E., Gu, J., Schau, M. & Bunn, H. F. Regulation of hypoxia-inducible
factor 1alpha is mediated by an O2-dependent degradation domain via the
ubiquitin-proteasome pathway. Proceedings of the National Academy of Sciences
of the United States of America 95, 7987–92 (1998).

6.

Forsythe, J. a et al. Activation of vascular endothelial growth factor gene
transcription by hypoxia-inducible factor 1. Molecular and cellular biology 16,
4604–13 (1996).

7.

Pugh, C. W. & Ratcliffe, P. J. Regulation of angiogenesis by hypoxia: role of the
HIF system. Nature medicine 9, 677–84 (2003).

8.

Berra, E., Roux, D., Richard, D. E. & Pouysségur, J. O 2 -driven proteasomal
degradation irrespective of its subcellular localization  : nucleus or cytoplasm. 2,
615–620 (2001).

9.

Bruick, R. K. & McKnight, S. L. A conserved family of prolyl-4-hydroxylases that
modify HIF. Science (New York, N.Y.) 294, 1337–40 (2001).

10.

Bruick, R. K. Oxygen sensing in the hypoxic response pathway: regulation of the
hypoxia-inducible transcription factor. Genes & development 17, 2614–23 (2003).

11.

Jaakkola, P. et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation
complex by O2-regulated prolyl hydroxylation. Science (New York, N.Y.) 292,
468–72 (2001).

12.

Ivan, M. et al. HIFalpha targeted for VHL-mediated destruction by proline
hydroxylation: implications for O2 sensing. Science (New York, N.Y.) 292, 464–8
(2001).

	
  

24	
  

13.

Schofield, C. J. & Ratcliffe, P. J. Oxygen sensing by HIF hydroxylases. Nature
reviews. Molecular cell biology 5, 343–54 (2004).

14.

Schofield, C. J. & Ratcliffe, P. J. Signalling hypoxia by HIF hydroxylases.
Biochemical and biophysical research communications 338, 617–26 (2005).

15.

Lando, D., Peet, D. J., Whelan, D. a, Gorman, J. J. & Whitelaw, M. L. Asparagine
hydroxylation of the HIF transactivation domain a hypoxic switch. Science (New
York, N.Y.) 295, 858–61 (2002).

16.

Lando, D. et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the
transcriptional activity of hypoxia-inducible factor. Genes & development 16,
1466–71 (2002).

17.

Lando, D. et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the
transcriptional activity of hypoxia-inducible factor. Genes & development 16,
1466–71 (2002).

18.

Hewitson, K. S. et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is
identical to factor inhibiting HIF (FIH) and is related to the cupin structural family.
The Journal of biological chemistry 277, 26351–5 (2002).

19.

Berra, E. et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low
steady-state levels of HIF-1alpha in normoxia. The EMBO journal 22, 4082–90
(2003).

20.

Hirsilä, M., Koivunen, P., Günzler, V., Kivirikko, K. I. & Myllyharju, J.
Characterization of the human prolyl 4-hydroxylases that modify the hypoxiainducible factor. The Journal of biological chemistry 278, 30772–80 (2003).

21.

Aprelikova, O. et al. Regulation of HIF prolyl hydroxylases by hypoxia-inducible
factors. Journal of cellular biochemistry 92, 491–501 (2004).

22.

Hewitson, K. S. & Schofield, C. J. The HIF pathway as a therapeutic target. Drug
discovery today 9, 704–11 (2004).

23.

Speer, R. E. et al. Hypoxia-inducible factor prolyl hydroxylases as targets for
neuroprotection by “antioxidant” metal chelators: From ferroptosis to stroke. Free
radical biology & medicine 62, 26–36 (2013).

24.

Appelhoff, R. J. et al. Differential function of the prolyl hydroxylases PHD1,
PHD2, and PHD3 in the regulation of hypoxia-inducible factor. The Journal of
biological chemistry 279, 38458–65 (2004).

25.

Choi, K. et al. Inhibition of the Catalytic Activity of Hypoxia-Inducible Factor- 1
␣ -Prolyl-Hydroxylase 2 by a MYND-Type Zinc Finger. 68, 1803–1809 (2005).

	
  

25	
  

26.

Myllyharju, J. Prolyl 4-hydroxylases, master regulators of the hypoxia response.
Acta physiologica (Oxford, England) 208, 148–65 (2013).

27.

Metzen, E. Intracellular localisation of human HIF-1alpha hydroxylases:
implications for oxygen sensing. Journal of Cell Science 116, 1319–1326 (2003).

28.

Ehrismann, D. et al. Studies on the activity of the hypoxia-inducible-factor
hydroxylases using an oxygen consumption assay. The Biochemical journal 401,
227–34 (2007).

29.

Metzen, E. Enzyme substrate recognition in oxygen sensing: how the HIF trap
snaps. The Biochemical journal 408, e5–6 (2007).

30.

Rich, T. C. et al. HIF-1 ␣ binding to VHL is regulated by stimulus- sensitive
proline hydroxylation. 98, (2001).

31.

Choi, K. et al. Inhibition of the Catalytic Activity of Hypoxia-Inducible Factor- 1
␣ -Prolyl-Hydroxylase 2 by a MYND-Type Zinc Finger. 68, 1803–1809 (2005).

32.

Song, D. et al. Prolyl hydroxylase domain protein 2 (PHD2) binds a Pro-Xaa-LeuGlu motif, linking it to the heat shock protein 90 pathway. The Journal of
biological chemistry 288, 9662–74 (2013).

33.

Zhou, J. et al. Substrate Binding to the r -Ketoglutarate-Dependent Non-Heme Iron
Enzyme Clavaminate Synthase 2  : Coupling Mechanism of Oxidative
Decarboxylation and Hydroxylation. 13539–13540 (1998).

34.

Hausinger, R. P. FeII/alpha-ketoglutarate-dependent hydroxylases and related
enzymes. Critical reviews in biochemistry and molecular biology 39, 21–68
(2004).

35.

Hoffart, L. M., Barr, E. W., Guyer, R. B., Bollinger, J. M. & Krebs, C. Direct
spectroscopic detection of a C-H-cleaving high-spin Fe(IV) complex in a prolyl-4hydroxylase. Proceedings of the National Academy of Sciences of the United
States of America 103, 14738–43 (2006).

36.

Price, J. C., Barr, E. W., Tirupati, B., Bollinger, J. M. & Krebs, C. The first direct
characterization of a high-valent iron intermediate in the reaction of an alphaketoglutarate-dependent dioxygenase: a high-spin FeIV complex in taurine/alphaketoglutarate dioxygenase (TauD) from Escherichia coli. Biochemistry 42, 7497–
508 (2003).

37.

Grzyska, P. K. et al. Steady-state and transient kinetic analyses of taurine/alphaketoglutarate dioxygenase: effects of oxygen concentration, alternative sulfonates,
and active-site variants on the FeIV-oxo intermediate. Biochemistry 44, 3845–55
(2005).

	
  

26	
  

CHAPTER II

SUBSTRATE SELECTIVITY OF PHD2
2.1

Introduction
Oxygen homeostasis in humans and other metazoans is transcriptionally regulated

by the hypoxia inducible factor-1α (HIF-1α)1,2, which governs cellular responses to
hypoxia, such as the balance of aerobic/anaerobic metabolism, angiogenesis, and
erythropoiesis.

HIF-1α stability is controlled by the HIF-prolyl hydroxylases (PHD1,

PHD2 and PHD3 in humans)3,4, which hydroxylate specific Pro residues found in the Nand C-terminal O2-dependent degradation domains of HIF-1α: NODD (Pro402) and the
CODD (Pro564), leading to proteasomal degradation of HIF-1α5,6. Hydroxylation of
either Pro402 or Pro564 is sufficient to for HIF-1a to bind tightly to pVHL5,6, leading to
proteasomal degradation7. A key question in this field is substrate selectivity of PHD
isoforms toward the ODD domains, as this determines the stability of HIF-1α. As PHD2
is thought to be the primary O2-sensor under normoxic conditions8, and it is the only
PHD isoform with a high-yield recombinant expression, detailed enzymological studies
of PHD2 are important both to understand the chemical mechanisms of prolyl
hydroxylation, as well as to identify the basis for substrate selectivity in PHD2 and
related enzymes.
PHD2 is a non-heme Fe(II), 2-oxoglutarate (2OG)-dependent oxygenase that is
thought to follow the consensus mechanism for related oxygenases (Scheme 2.1)9–11. In
this ordered mechanism, substrates bind in the order 2OG, primary substrate (ODD), then
O2. Binding of the primary substrate triggers O2 binding by inducing the formation of a
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5-coordinate Fe(II) cofactor10,12, and associated changes to local contacts within the
active site.

Oxidative decarboxylation leads to formation of a putative Fe(IV)O

intermediate13–15 (Scheme 2.1), which effects hydroxylation of the target Pro residue
(CODD, Pro564; NODD, Pro402) to complete the cycle.

As the half-reactions are

sequential, oxidative decarboxylation that is uncoupled from hydroxylation can occur16,
leading to excessive consumption of 2OG in some cases.

Scheme 2.1 Consensus mechanism and ODD sequences.
Cell-based assays have shown that the PHD isoforms exhibit differential
selectivity toward the ODD domains, with PHD2 reacting more rapidly with CODD than
NODD in HIF-1α constructs17. Immunoblotting showed CODD hydroxylation prior to
NODD hydroxylation in cell-based assays suggesting some level of synergy between the
two sites18, however binding assays of very long ODD constructs revealed that CODD
bound to purified PHD2 with roughly ten-fold increased affinity relative to NODD19,
suggesting that intrinsic binding affinity may explain the apparent hydroxylation order.
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Due to the complicated relationship between local and extended ODD sequences on
PHD2 activity18,20, we used short peptides (~20 residues) containing the local ODD
sequences to test for local effects on the substrate selectivity of PHD2.
There are conflicting reports as to the substrate selectivity of PHD2 toward the
two ODD domains, as the reactions of PHD2 with NODD and CODD have been reported
with widely varying rates (kcat/KM) and Michaelis constants (KM). Early reports based on
2OG consumption assays were widely divergent in terms of reported KM values. Assays
using PHD2 within crude cell lysates indicated a strong preference for CODD (KM(NODD)
= 130 µM, KM(CODD) = 7 µM)21; whereas assays using purified PHD2 indicated essentially
equivalent substrate preferences: (KM(NODD) = 44 µM, KM(CODD) = 37 µM)19. In contrast,
O2-consumption assays using purified PHD2 indicated a marked preference for CODD
(KM(NODD) = 24 µM, KM(CODD) = 2 µM), differing from the results of the 2OG assay22.
Although the biochemical data indicate that CODD is preferred , the wide variation in KM
presents a challenge to understanding how the rates relate to substrate binding for PHD2.
The large variation in reported values for the Michaelis constants, with KM(NODD)
values ranging from 20 – 50 mM and KM(CODD) values ranging from 1 – 30 mM17,19,23, is
largely a reflection of three factors that introduce variation into the kinetic data, two of
which are common to the broad class of 2OG oxygenases. First is the inherent difficulty
of measuring turnover for the 2OG oxygenases, due to the relatively slow rate of turnover
and the absence of chromophoric substrates. This has lead to a reliance in many reports
on the decarboxylation assay that measures the release of

14

CO2 from [1-14C]2OG.

Second is the tendency for 2OG oxygenases to uncouple oxidative and reductive halfreactions, leading to decarboxylation without substrate hydroxylation24–26. This in turn
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greatly impacts assays that rely on the rate of CO2 liberation or O2 consumption, and
certainly leads to over-estimation of turnover rates. Third is the pKA = 7.2 of the Fe2+OH2 group in (Fe+2OG)PHD223, leading to a significant decrease in activity as pH is
increased above the pKa27.

Based on these divergent Michaelis constants, and the

potential for uncoupled oxidative decarboxylation to inflate the observed rates, we felt
that the substrate preference and rates could be better defined by directly measuring the
formation of hydroxylated product (ODDOH) using MALDI-TOF28,29.
It appears that PHD2 may discriminate NODD from CODD due to a combination
of electrostatics and a conformational change of the b2b3 loop (Fig. 1). Closure of the
b2b3 loop is essential for tight ODD binding, as shown by the crystal structure of
CODD/(Mn+NOG)PHD230, and activity assays with chimeric PHD enzymes7. Sequence
comparison shows that CODD contains six acidic residues, compared to three for NODD
(Scheme 1), suggesting that electrostatics may be the origin of differential binding – this
is supported by the sequence preference of PHD2 (–AP(Y/F)(I/L)X4(D/E)–) obtained
from yeast two-hybrid binding assays31. Further, protease susceptibility assays showed
that CODD/PHD2 was greatly stabilized relative to NODD/PHD2, both in terms of the
length of time required for proteolysis as well as in the proteolytic site on the b2b3 loop
stabilized by ODD binding32.
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Figure 2.1 Structure of (Mn+NOG)PHD2 bound to CODD [30] showing the β2β3 loop
(red) and CODD (cyan) PDB IDs:3HQR and 2G19.

The contribution of ODD/PHD2 binding to the catalytic efficiency of PHD2
(kcat/KM) is not fully defined, despite its importance to O2 sensing. Catalytic efficiency
dictates the rate constant under conditions of low substrate concentration, and provides
insight into the basis for discriminating NODD from CODD.

Microscopic steps

contributing to kcat/KM include those steps between the diffusional collision with ODD
through the first irreversible step – as a consequence, weaker binding of NODD relative
to CODD could constitute the entire basis for substrate selectivity of PHD2.
Furthermore, binding equilibria can contribute to overall rate-limitation, making
understanding the binding ODD/PHD2 process a key factor in understanding the
chemistry of O2-sensing.
Here we tested the origin of substrate selectivity of PHD2 by direct competition
assays, increased ionic strength, and global protein flexibility for PHD2 upon binding
ODD. Our results indicate that PHD2 prefers CODD by 20-fold over NODD, and that
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electrostatics accounts for approximately 15% of this effect. We also performed global
hydrogen deuterium exchange experiments (HDX) with the aim of monitoring possible
different structural changes upon binding of each substrate to the enzyme. Our global
HDX data reveals that binding of Fe(II) and 2OG to the enzyme active site stabilizes the
overall enzyme structure as reported previously by proteolysis studies32, however we
noted a crucial difference from that earlier report.

At saturating concentrations of

substrate, CODD and NODD gave indistinguishable HDX profiles, which strongly
suggests that both substrates stabilize the b2b3 loop to the same extent. This implicates
loop closure as the dominant contributor to selectivity in PHD2.
2.2

Experimental Procedures

2.2.1 Materials
All chemicals were purchased from commercial vendors, and used without
purification with the exception of NODD. The sequences of the peptide substrates were
derived from the native HIF-1α395-414 (NODD) and HIF-1α556-574 (CODD) sequences.
The

sequence

of

the

NODD

DALTLLAP402AAGDTIISLDYG

peptide

and

the

used

in

CODD

this

work

peptide

was
was

DLDLEALAP564YIPADDDFQL. The underlined residues were changed from the native
sequences as follows: NODD (F413Y), CODD (M561A, M568A). The NODD peptide
(desalted) was purchased from EzBiolab (Carmel, IN, USA) and purified by C18 column
reversed phase-HPLC using an H2O/CH3CN gradient (5 - 95% CH3CN, 0.1% TFA),
whereas the CODD peptide (99 % purity) was purchased from GL Biochem LTD
(Shanghai).
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2.2.2 Protein expression and purification
Recombinant human PHD2 (corresponding to residues 178-426 of the full-length
PHD2 sequence) was expressed and purified as previously reported23.

PHD2 was

expressed with an N-terminal GST tag (GST-PHD2) in E. coli BL21(DE3) cells using a
pGEX-4T-1 vector (Stratagene). The GST-PHD2 fusion was purified using an affinity
column (GSTrap, GE Bioscience), then the GST tag was removed by incubating GSTPHD2 with restriction grade thrombin for 16 hours at 4 oC. Thrombin was removed by a
Hitrap Benzamidine column (GE Bioscience), and un-cleaved GST-PHD2 and GST was
removed with a GSTrap column. PHD2 was treated with 50 mM EDTA then buffer
exchanged into 50 mM HEPES pH 7.00 and stored at - 20.0 oC. PHD2 purity was
checked by SDS-PAGE, and the molecular weight determined using a QStar-XL hybrid
quadrupole-TOF mass spectrometer (Applied Biosystems).
2.2.3 Steady-state kinetic assays
All activity assays were performed with saturating concentrations of 2OG (100
µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1 mM), and 1 µM PHD2 in 50 mM HEPES
pH 7.00 at 37.0 oC. Reactions were quenched at different time points with 2:1 ratio of
acetonitrile and 0.2 % trifluoroacetic acid saturated with 4-α-cyano hydroxycinnamic
acid. Samples were then spotted onto a target plate and analyzed by a Bruker Daltonics
Omniflex MALDI-TOF mass spectrometer. Initial rates (v0) were obtained from the
temporal change in mol fraction of hydroxylated ODDOH (cODDOH), as v0 = [ODD]0
cODDOH /t.
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2.2.4 Global hydrogen deuterium exchange (HDX) kinetics of PHD2
Global HDX experiments were measured with an ABI QStar-XL mass
spectrometer. PHD2 (50 µM) was pre-incubated in 10 mM NH4OAc at pH 7.00 on ice
with the cofactor and substrates as indicated: MnSO4 (200 µM), 2OG (1.0 mM), and
CODD or NODD (0 - 500 µM). Mn2+ was used as a structural mimic of Fe2+ in order to
avoid spurious oxidation. The HDX reactions were initiated by diluting 3 µL of PHD2
samples with 27 µL 10 mM NH4OAc (in D2O) pD 7.00 at 25 oC, with aliquots quenched
by injecting onto an HPLC loop at various time points from 15 second to 60 minutes.
Solution pD was determined by adding 0.4 to the pH meter reading (pD = pHmeter + 0.4).
HDX aliquots (20 µL) were injected and buffer exchanged using a C18 HPLC column
with a 0.1 % formic acid (pH 2.5) mobile phase. The HPLC column, injection loop, and
mobile phases were kept in an ice bath to minimize amide back exchange during sample
workup. PHD2 was eluted with a 10 minute gradient, (H2O / CH3CN, 0.1% formic acid),
and was directly sprayed into an ABI QStar-XL for determination of global deuterium
incorporation level. Data was analyzed using the Bioanalyst software.
During analysis of HDX samples some amide hydrogens can back exchange with
the HPLC solvent, leading to an apparent loss of deuteration. In order to correct for back
exchange occurring during the LC steps, the deuterium content of PHD2 at each quench
point was corrected through comparison with the mass of a non-deuterated sample (m0)
and the mass of a fully deuterated PHD2 sample (m100). The fully deuterated protein was
prepared by incubation in D2O for a day at 37.0 oC followed by 10 minutes at 70 oC. The
number of exchangeable backbone amides (D) was then calculated by subtracting the
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number of Pro residues (12) and the N-terminus from of the total number of
exchangeable amides on PHD2 (N = 236).
D = N × (mobs – m0)/(m100 – m0)
2.3

Results

2.3.1 PHD2 shows a preference for CODD over NODD in the presence of both
substrates
PHD2 hydroxylates Pro402(NODD) and Pro564(CODD) of HIF-1α, however,
reports conflict as to the relative substrate preference. Some reports indicated that both
Pro residues were hydroxylated at a similar rate, whereas other reports suggested that
CODD was hydroxylated at a faster rate than NODD. In order to determine the substrate
selectivity of PHD2 activity assays were performed under competitive conditions in the
presence of 20 µM total substrate, but with a varying ratio of NODD:CODD. As we
directly monitored hydroxylation via MALDI, both CODD and NODD could be
measured simultaneously. The initial rates for hydroxylation of both ODDs were plotted
as a function of varied mole fraction of NODD (Figure 2.1). As χNODD was increased, the
initial rate for CODD hydroxylation decreased from 1.3 min-1 to 0.8 min-1; conversely,
the initial rate for NODD hydroxylation increased from 0.04 min-1 to 0.6 min-1. This data
shows that PHD2 preferentially hydroxylated CODD in the presence of NODD even at
elevated mole fraction of NODD (Figure 2.1).
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Figure 2.2 Substrate selectivity of PHD2 under competitive condition. PHD2 (1 µM),
2OG (100 µM), ODD (2-18 µM; 20 mM total), (NH4)2Fe(SO4)2 (10 µM) and ascorbic
acid (1 mM) in 50 mM HEPES pH 7.00 at 37 oC. (CODD (o), NODD (●)).

2.3.2 Columbic forces are essential in substrate preference of PHD2
Crystallography showed the ODD-binding surface of PHD2 contained several
basic residues whereas the ODD substrates contain acidic residues flanking the LXXLAP
motif suggesting that electrostatics may be important in binding substrates to PHD2. In
order to test the role of electrostatics in PHD2 substrate recognition, activity assays were
performed in the presence of varied NaCl concentration. The initial rates of PHD2 were
measured as a function of varying ODD concentration in the presence and in the absence
of 100 mM NaCl, then the rate constants kcat and kcat/KM were determined by fitting the
data to the Michaelis-Menten equation (Table 2.1).
In the absence of NaCl, the kcat/KM value for CODD (1.0 µM-1min-1) was 25 fold
higher than kcat/KM for NODD (0.04 µM-1min-1) showing that PHD2 was more reactive
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toward CODD than NODD (Figure 2.3 and Table 2.1). The addition of 100 mM NaCl
did not alter the kcat/KM value of NODD (0.05 µM-1min-1) but decreased the kcat/KM for
CODD (0.3 µM-1min-1), indicating that attractive columbics were operative in
CODD/PHD2 binding, but not in NODD/PHD2 binding.

Figure 2.3 The effect of 100 mM NaCl on the kinetics of ODD hydroxylation by PHD2.
PHD2 was incubated with saturating 2OG (100 µM), (NH4)2Fe(SO4)2 (10 µM), and
ascorbic acid (1 mM), but varied ODD (0 – 50 mM) in 50 mM HEPES pH 7.00 at 37.0
o
C. CODD, (o) no NaCl added and (●) 100 mM NaCl added. NODD, (Δ) no NaCl
added and (▲) 100 mM NaCl added.
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Table 2.1 Steady state kinetic constants for PHD2 using CODD or NODD.
Substrate peptide
CODD (0 mM NaCl)

kcat (min-1)
1.13 ± 0.05

CODD (+ 100 mM NaCl)
NODD (0 NaCl)

kcat/KM (µM-1min-1) KM (µM)

1.18 ± 0.12

0.61 ± 0.06

NODD (+ 100 mM NaCl)

1.01 ± 0.11
0.29 ± 0.06

0.04 ± 0.01

0.62 ± 0.04

1.04 ± 0.30
4.15 ± 1.21

13.53 ± 2.61

0.05 ± 0.01

11.23 ± 2.37

Fixed concentrations of 2OG (100 µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic acid
(1 mM), and ambient O2 (217 mM), but varied ODD (0 – 50 mM) in 50 mM HEPES pH
7.00 at 37.0 oC
2.3.3 NODD and CODD bind equivalently to PHD2
Global amide HDX was used to test solvent protection of PHD2 upon binding
NODD and CODD. Apo PHD2 (no added substrate or cofator) and (Mn+2OG)PHD2
were analyzed as reference states, in which Mn(II) was used as a isosteric replacement
for Fe(II). Solvent protection of NODD/(Mn+2OG)PHD2 and CODD/(Mn+2OG)PHD2
was measured under conditions of both low (20 mM) and high (50 mM) ODD
concentrations to observe the effects of the ODD/PHD2 binding equilibrium. Amide
HDX timecourses (Figure 2.4) for PHD2 in different cofactor/substrate bound states were
fitted by binning the amides into three pools (An) based on average exchange rates: fast
(kfast = 20 min-1), intermediate (kmed = 1 min-1), slow (kslow = 0.05 min-1); the remaining
amides were inaccessible to D2O solvent.
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Figure 2.4 Global amide HDX kinetics of PHD2. (■) PHD2 (5 µM) in 10 mM NH4OAc
pH 7.0, (○) PHD2 (5 µM), MnSO4 (20 µM), and 2OG (100 µM) (●) PHD2 (5 µM),
MnSO4 (20 µM) 2OG (100 µM), and NODD (50 µM), (▲) PHD2 (5 µM), MnSO4 (20
µM), 2OG (100 µM), and CODD (50 µM). Inset: low concentration conditions, [NODD]
or [CODD] = 20 mM.

Amide exchange occurs from solvent-exposed amides, which are those located in
transiently unfolded or unstructured regions of the protein. Solvent-protected amides are
those that are either buried within a tightly structured core of the protein, or else are
located at a macromolecular binding surface. The key pool for interpreting the PHD2
conformational change are the inaccessible amides (Afrozen), as these are either buried in
the folded core of the PHD2, or protected from solvent by ODD binding.
Solvent protection for PHD2 increased upon cofactor binding, as seen comparing
(Mn+2OG)PHD2 to apo PHD2. The frozen amide population increased from Afrozen = 26
in Apo PHD2 to Afrozen = 59 in (Mn+2OG)PHD2, indicating that the core of the PHD2
had become more tightly structured upon binding cofactor (Table 2.2). This is likely due
to the stabilizing effect of metal and 2OG binding, which connects several strands of the
b-barre30,33.
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Binding of NODD or CODD under saturating conditions (50 µM) led to
equivalent increases in the froze amide pool when compared with (Mn+2OG)PHD2
(Table 2.2).

The 50 mM NODD/(Mn+2OG)PHD2 sample exhibited an appreciable

increase in the frozen amide pool (Afrozen = 70), which is most likely due to solvent
protection at the binding interface. A nearly identical increase in the frozen amide pool
was observed for the 50 mM CODD/(Mn+2OG)PHD2 sample (Afrozen = 73). The small
difference in the frozen amide pool between the NODD and CODD samples (DAfrozen =
3) is within experimental uncertainty, and strongly suggests that both NODD and CODD
bind to the same surface of PHD2, stabilizing the b2b3 loop to equivalent extents.
In contrast, the binding of NODD or CODD at low concentrations (20 mM) led to
different frozen amide pools relative to (Mn+2OG)PHD2 (inset, Figure 2.4). The large
difference in frozen amide population for 20 mM NODD binding relative to 20 mM
CODD binding (DAfrozen = 14) is well outside of experimental uncertainty, and indicates a
difference in binding equilibrium. This is most likely due to the stronger binding of
CODD (KM = 1 mM) relative to NODD (KM = 13 mM), and the position of the ODD +
PHD2 binding equilibrium.
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Table 2.2 Global amide HDX kinetics of PHD2.a, b
Apo

Atot

(Mn+2OG)

20 mM

20 mM

50 mM

50 mM

NODD

CODD

NODD

CODD

(Mn+2OG)

(Mn+2OG)

(Mn+2OG)

(Mn+2OG)

210 ± 1

177 ± 1

171 ± 1

157 ± 1

166 ± 1

163 ± 1

Afast 160 ± 2

128 ± 2

116 ± 3

85 ± 3

105 ± 3

87 ± 3

Amed 31 ± 2

31 ± 2

36 ± 3

48 ± 3

42 ± 3

53 ± 3

Aslow 19 ± 1

18 ± 2

20 ± 2

24 ± 2

18 ± 2

24 ± 2

Afrozen 26

59

65

79

70

73

a. Accessible amides: total, Atot; slow, Aslow, (kslow = 0.05 min-1); intermediate,
Amed (kmed = 1 min-1); fast, Afast (kfast = 20 min-1).
b. PHD2 (5 µM) in 10 mM NH4OAc pH 7.00, MnSO4 (20 µM) and 2OG (100
µM); NODD and CODD as indicated.
2.4

Discussion
The substrate selectivity of PHD2 has been subject to conflicting literature

reports, which have been clarified with the present work using purified PHD2 and short
ODD peptides. Most prior reports indicated that CODD was preferred over NODD,
however the Michaelis constants (KM) and catalytic efficiency of PHD2 (kcat/KM) have
been subject to variations of ~ 10-fold. These variations likely arose from complications
with the various assays used to measure turnover. We used kinetic assays that directly
measure the formation of hydroxylation product (ODDOH) to avoid potential
complications from uncoupled oxidations or side-reactions that may impede the 2OG
assay. Our amide HDX approach directly measured solvent protection upon binding
NODD or CODD, in order to compare the binding footprints of these two substrates.
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Our kinetics data indicate that PHD2 prefers the CODD substrate by ~20-fold
over the NODD substrate (Table 2.1, kcat/KM). Further, this substrate preference using
short peptides is sufficient to explain the relative order of hydroxylation observed in
longer ODD constructs17,18,34, without the need to invoke any sort of sequential crosscommunication between the ODD segments in HIF-1a. These observations were in good
agreement with the KM values obtained by the O2-consumption assay22, but differed
significantly from those obtained by the 2OG assay19,21. It appears that the 2OG assays
suffer from non-ideal behavior at low substrate concentrations leading to inflated KM.
This may be due to uncoupling of oxidative decarboxylation or from non-enzymatic
decarboxylation, contributing to the observed rates of 2OG turnover. By measuring
ODDOH formation directly, the MALDI assay used herein avoided these complications,
and is recommended for steady-state kinetics assays.
Direct competitive experiments under varying CODD:NODD ratios (Figure 2.2)
indicated that PHD2 prefers to hydroxylate CODD, even at low CODD:NODD ratio –
consequently, CODD should be hydroxylated first under physiological conditions. This
is as expected based solely on the catalytic efficiency of PHD2 toward these two
substrates (Table 2.1). These results are in accord with a prior competition assay19,
however our results were obtained at low concentrations of substrate ([NODD] +
[CODD] = 20 mM), corresponding to conditions appropriate for discussing catalytic
efficiency.
The substrate preference of PHD2 is a direct product of the catalytic efficiency
(kcat/KM) of this enzyme, which is largely a result of differential substrate binding. A
minimal kinetic model for catalysis at sub-saturating ODD includes diffusional encounter
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and release (k1 and k2), a kinetically coupled b2b3 loop closure (k3 and k4), and then
subsequent steps including the oxidative decarboxylation. Our results, combined with
existing structural and protease susceptibility data30,32, indicate that there are two coupled
steps necessary for substrate binding: diffusional encounter (k1) and b2b3 loop closure
(k3).
E + ODD

k1
k2

ODD/E

k3
k4

ODD/E*

E + ODDOH

As CODD has 6 negatively charged residues and NODD has only 3 negatively
charged residues, we thought it likely that electrostatic attraction to PHD2 would be more
pronounced for CODD than for NODD.

We observed that adding 100 mM NaCl

decreased the catalytic efficiency of PHD2 toward CODD (kcat/KM) by ~ 3-fold, but had
no effect on the reaction with NODD (Table 2.1). This is most likely due to an increase
in the rate of substrate release (k2) for CODD at elevated [NaCl]; nevertheless, this did
not equalize the substrate affinity. We note that CODD remained ~ 7 fold better as a
substrate than NODD, even at 100 mM NaCl, which requires that a subsequent step
discriminate these two substrates. This subsequent step is most likely to be closure of the
b2b3 loop to adopt a catalytically competent conformation, as seen crystallographically30.
Notably, PHD2 binding kinetics using substrates very similar to those used herein
showed that NODD and CODD bound to PHD2 with identical rates, but NODD release
was ~ 8 times faster than CODD in the presence of elevated [NaCl]19. This difference in
binding affinity is in excellent agreement with the difference in catalytic efficiency
toward the two substrates, which indicates that binding is the principle origin of substrate
selectivity in PHD2.
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Previously, protease susceptibility revealed greater protection of the b2b3 loop
from protease digestion for CODD/PHD2 than for NODD/PHD232, which was
interpreted to indicate that CODD bound to a larger surface of PHD2 than NODD. In
contrast, our global amide HDX data shows that both NODD and CODD protect PHD2
to identical extents, suggesting that these substrates bind to identical surfaces. This
discrepancy arises, in our opinion, from the weaker binding equilibrium for
NODD/PHD2 than for CODD/PHD2, as shown by the amide protection data shown in
Figure 2.4.
The closed conformation of the b2b3 loop in the CODD/PHD2 structure

30

suggested that loop closure plays a role in catalysis. We tested the relative ability of
CODD and NODD to induce the closed conformation of this loop at low and high [ODD]
concentrations using global amide HDX/MS. Amide HDX is uniquely capable of testing
ODD/PHD2 binding, reporting on changes in solvent access upon ODD binding. NODD
or CODD led to identical solvent protection when both were present at saturating
concentrations (50 mM) (Figure 2.4). The simplest interpretation of this data is that the
b2b3 loop of PHD2 was stabilized in the closed conformation to the same extent for
either substrate.
In contrast, the use of moderate ODD concentrations (20 mM) revealed
differences in solvent protection (Figure 2.4). These differences are simply the result of
the tighter binding of CODD (KM = 1.2 mM), than of NODD (KM = 14 mM); as
CODD/PHD2 is saturated under this condition, whereas NODD/PHD2 is not saturated –
CODD/PHD2 is fully protected from solvent whereas NODD/PHD2 is only partially
protected. As both NODD and CODD induce identical amide protection when fully
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saturating, it is very likely that the substrate selectivity of PHD2 does not arise from
altered ODD/PHD2 contacts, as previously suggested32, but rather from CODD being
able to push the equilibrium for b2b3 loop closure forward.
Although the rate-limiting step for PHD2 turnover remains to be identified, this
step precedes decarboxylation when ODD is saturating, as no oxidized intermediates
were observed in the pre-steady state35, and a slightly inverse solvent isotope effect on
kcat was observed23. The results reported herein suggest that the kinetically coupled
closing of the b2b3 loop may limit the rate of turnover under conditions of low ODD
concentration. This has important ramifications for the physiological function of PHD2,
for two key reasons. First, it indicates that CODD is hydroxylated before NODD simply
due to the catalytic efficiency of PHD2 toward these substrates. Second, it suggests the
potential to regulate PHD2 function by post-translational modifications that alter the
charge of either the ODDs or the β2β3 loop of PHD2 (eg: phosphorylation), as this would
directly impact the ability PHD2 to bind the ODD.
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CHAPTER III

THR387 IS THE KEY RESIDUE IN O2 ACTIVATION OF PHD2
3.1

Introduction
HIF prolyl-4-hydroxylase 2 (PHD2) is a non heme Fe(II), 2-oxoglutarate (2OG)

dependent oxygenase that serves as the primary O2 sensor in human cells1,2. PHD2
regulates the transcriptional activity of the HIF-1α transcription factor by hydroxylating
Pro402 and Pro564 within the oxygen dependent degradation domain (ODD) of HIF-1α1,3–5.
Involvement

of

HIF-1α

in

aerobic/anaerobic

metabolism,

angiogenesis,

and

erythropoiesis makes the PHD2 target for HIF-1α mediated disease6–8. In order for
PHD2 function it requires O2, Fe(II), 2OG, and ascorbic acid to keep the Fe(II) in
reduced state1,9–11. PHD2 active site is six coordinate, Fe(II) cofactor coordinated with a
common His2Asp facial triad.

Binding HIF-1α-ODD stimulates hydroxylation by

PHD212, which is the basis for hypoxia sensing in human cells. As HIF-1α hydroxylation
underlies angiogenesis and the balance between aerobic metabolism and fermentation,
PHD2 is an important therapeutic target for diseases such as ischemia, anemia, and
cancer6,7. The mechanical linkage whereby HIF-1α binding stimulates hydroxylation
chemistry is poorly understood.
PHD2 is thought to follow the consensus chemical mechanism for 2OG
oxygenases (Scheme 3.1)12–14. The (Fe+2OG)PHD2 form of enzyme contains an Fe(II)
cofactor coordinated by a facial triad, a bidentate 2OG ligand, and an aquo ligand. When
substrate ODD binds the enzyme becomes 15-fold more reactive toward O2, which is
typically attributed to the release of this aquo ligand creating a binding site for O2.
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Oxidative decarboxylation generates the Fe(IV)-oxo, an intermediate that has been
observed in other related enzymes12,13,15,16. This Fe(IV)-oxo hydroxylates the Proline
residue, regenerating the Fe(II) cofactor (Scheme 3.1). For those enzymes in which the
Fe(IV)-oxo intermediate has been observed, product release or decomposition of the
Fe(IV)-oxo appear to be rate-limiting steps12,13,15,16.

Notably, the HIF hydroxylase

enzymes appear to be rate-limited by a step associated with O2 binding or activation, as
the Fe(IV)-oxo intermediate did no accumulate in the pre-steady state for PHD214 and
both PHD2 and FIH exhibit inverse solvent KIEs17,18.
The X-ray crystal structure of (Fe+2OG)PHD219 showed that the aquo ligand is
part of an extended hydrogen bonding network connecting to the second coordination
sphere. The network is an extended hydrogen bond extending from the aquo ligand
through an ordered H2O, which connects the aquo ligand to 2OG and Thr387 (Figure 3.1).
Thr387 is located on the back beta-sheet at a position that forms a conserved indirect Hbond to the aquo ligand in many 2OG oxygenases20. As a step associated with O2
activation or binding is likely the rate-determining step for PHD2, the disposition of
Thr387 may be crucial to mechanically link ODD binding to O2 activation and Pro564
hydroxylation by PHD2.
Here we tested the role of Thr387 in hydroxylation chemistry by PHD2 through
point mutagenesis and steady state kinetics. Both a Thr387 àAla mutation was prepared
to eliminate H-bonding potential at this site, as well as a conservative Thr387 àAsn
mutation that would retain the H-bonding potential. Our steady state kinetic experiments
indicated that conserving this H-bond led to a mutant enzyme that was very similar to
WT-PHD2, but that removing this H-bond significantly altered the rate of CODD
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hydroxylation. Remarkably, the Thr387àAla mutant hydroxylated CODD 15 times faster
than WT-PHD2, due to a change in rate-limiting step as shown by an increased SKIE
(D2Okcat > 1) and an increased kcat/KM(O2) from those observed with WT-PHD2. This led
to two important kinetic signatures that we attributed to succinate release becoming the
rate-limiting step in the Thr387àAla mutant. First, substrate inhibition of WT-PHD2 was
not observed, but it became pronounced in the Thr387àAla mutant, which strongly
implicates succinate release as a slow step in this mutant – a corollary is that other
substrate inhibition in other 2OG oxygenases likely reflects slow succinate release21.
Second, the KM(O2) decreased in the Thr387àAla mutant, most likely due to an increased
rate for O2 activation or decarboxylation.

Scheme 3.1 Consensus chemical mechanism of non heme Fe(II), 2OG dependent
oxygenases.
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Figure 3.1 PHD2 active site (PDB ID: 3OUJ). Waters (red sphere), distances (Å).
3.2

Materials and Methods

3.2.1 Materials
All chemicals were purchased from commercial vendors, and used without
purification.	
  	
  The sequences of the peptide substrates were derived from the native HIF1α556-574 (CODD)

sequence.

The

sequence

of

the

CODD

peptide

was

DLDLEALAP564YIPADDDFQL. The underlined residues were changed from the native
sequences as follows: CODD (M561A, M568A) to avoid methionine oxidation. The
CODD peptide (99 % purity) was purchased from GL Biochem LTD (Shanghai).
	
  
3.2.2 Protein expression and purification
Recombinant human PHD2178-426 and its mutants, Thr387àAla and Thr387àAsn
were expressed as a C-terminal fusion protein from E. coli BL21(DE3) cells using a
pGEX-4T-1 vector (Stratagene) and purified as previously described18,22. Briefly, PHD2GST was purified using an affinity column (GSTrap, GE Bioscience), then the GST-tag
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was cleaved with restriction grade thrombin for 16 hours at 4 oC. The thrombin was
removed with a Hitrap Benzamidine column (GE Bioscience), then PHD2 was treated
with 50 mM EDTA overnight to remove metals. PHD2 was buffer exchanged with 50
mM HEPES pH 7.50 and stored at -20 oC. The mass of the WT-PHD2 and the mutants
were determined by a QStar-XL hybrid quadrupole-TOF mass spectrometer (Applied
Biosystems). WT-PHD2 (27786.6 Da calculated, 27784.7 Da observed), Thr387àAla
(27755.2 Da calculated, 27756.2 Da observed), and Thr387àAsn (27799.6 Da calculated,
27798.2 Da observed).
3.2.3 Steady state kinetic assays
Steady-state kinetic constants were obtained from initial rate measurements using
MALDI-TOF.
Initial rates were measured under saturating concentrations of Fe2+ (10 µM) and
ascorbic acid (1 mM) in 50 mM HEPES buffer pH 7.00 at 37.0 oC. For assays in which
[2OG] was varied, the concentration of CODD was fixed at saturating levels for each
enzyme WT-PHD2 (10 µM), Thr387àAla (10 µM), and Thr387àAsn (10 µM). Reactions
were quenched at different time points in saturated 4-α-cyano hydroxycinnamic acid
dissolved in 75 % acetonitrile and 0.2 % trifluoroacetic acid. Quenched reactions were
spotted onto a MALDI target plate and analyzed using a Bruker Daltonics Omniflex
MALDI-TOF mass spectrometer.

For assays in which the [CODD] varied, the

concentration of 2OG was fixed at saturating levels for each enzyme WT-PHD2 (100
µM), Thr387àAla (100 µM), and Thr387àAsn (100 µM).

Observed masses of the

substrate peptide CODD (M + Na+) 2158 m/z calculated, 2156 m/z observed and
hydroxylated product CODDOH (MOH + Na+) 2174 m/z calculated, 2172 m/z observed.
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3.2.4 Intrinsic fluorescence quenching
The dissociation constant (KD) of 2OG was determined by measuring the
quenching of the intrinsic tryptophan fluorescence of PHD2 upon titrating 2OG using a
spectrofluorometer (PTI-QM-4 2005SE).

Samples were excited at 295 nm and the

emission measured at 330 nm. 1 µM PHD2 was titrated with 500 µM 2OG, change in the
emission intensity at 330 nm upon binding of 2OG was monitored. KD obtained by
fitting the data to equation 3.
Equation 3.
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!! !!!
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3.2.5 Kinetic solvent isotope effect experiments (KSIE)
Two different 50 mM HEPES buffers were prepared one with H2O and other with
D2O mM HEPES buffer prepared using D2O. Working stock solutions of 2OG, ascorbic
acid and CODD were prepared in 50 mM HEPES D2O and H2O buffers. Two different
set of initial rate measurements performed one with HEPES buffer prepared with H2O
and the other one with HEPES buffer prepared in D2O, under saturating concentrations of
Fe2+ (10 µM), 2OG (100 µM), ascorbic acid (1 mM) and [CODD] varied from 2 µM to
10 µM. KSIE determined as, the ratio of the reaction rate in H2O containing buffer to the
reaction rate in D2O containing buffer.
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3.2.6 Determination of KM(O2)
The initial rate measurements were performed under saturating concentrations of
Fe2+ (10 µM), 2OG (100 µM), and ascorbic acid (1 mM) in 50 mM HEPES pH 7.00 at 37
o

C. The concentration of dissolved O2 was varied by varying the ration of N2 and O2 gas

flowing through a gas waher in to an Atmosbag (SIGMA), with the dissolved O2
concentration monitored by a YSI model 5300 biological oxygen monitor. Reactions
were quenched and analyzed as for other steady state reactions.
3.3

Results

3.3.1 Steady state kinetics with varied [2OG]
The initial rate data for WT-PHD2 and the Thr387àAla/Asn were measured as a
function of varied [2OG] using saturating concentrations of Fe2+ (10 µM), CODD (10
µM), and ascorbate (1 mM); [O2] was fixed at ambient levels (217 uM). WT-PHD2
exhibited simple saturation kinetics over the range of 1 –200 µM 2OG, with fitted values
of kcat

(2.4 min-1) and kcat/KM(2OG) (2.03 µM-1min-1) similar to those previously

reported18,22–25. Similarly, the Thr387àAsn mutant exhibited saturation kinetics over the
tested concentration range, with modestly decreased rate constants (kcat = 1 min-1,
kcat/KM(2OG) = 1.5 µM-1min-1) (Table 3.1).
The initial rate data for Thr387àAla was a significant contrast to that of WTPHD2. The initial rate for product formation was measured at varied [2OG], with the
concentration of all other reagents fixed as above with the exception of CODD (10 µM).
Thr387àAla exhibited simple saturation kinetics for [2OG]<500 µM, however the kinetic
data for this mutant suggested the potential for substrate inhibition. Initial rate data over
a wider concentration range showed ~50% inhibition at 3000 µM 2OG (Figure 3.2).
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Fitting the initial rate data to the inhibition model led to fitted parameters of kcat (32.92
min-1), kcat/KM(2OG) (2.7 µM-1min-1), and KI(2OG) (2200 µM) indicative of substrate
inhibition. The high value for kcat indicated that Thr387àAla could perform chemistry
more rapidly than WT-PHD2, but the observed substrate inhibition suggested that slow
product release could limit turnover.
The substrate inhibition observed for Thr387àAla prompted us to test the other
variants for this effect. WT-PHD2 exhibited 5% inhibition at extremely high levels of
2OG; and fitting this data to the model substrate inhibition model did notsignificantly
change the steady state rate constants, kcat (2.3 µM), kcat/KM(2OG) (2.7 µM-1min-1), and
KI(2OG) (>25 mM) suggested that substrate inhibition was not pronounced for WT-PHD2.
Thr387àAsn similarly showed minimal inhibition at extremely high 2OG concentration,
with steady state rate constants virtually unchanged, kcat (1.0 min-1), kcat/KM(2OG) (1.5 µM1

min-1), and a very large estimate for KI(2OG) (>50000 µM) (Figure 3.3). The absence of

significant substrate inhibition observed for WT-PHD2 and for Thr387àAsn mutant was
consistent with product release being rapid in these enzymes, consistent with the prior
reports that implicated a step early in catalysis as being rate-limiting for WT-PHD2.
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Figure 3.2 Thr387àAla shows inhibition at high 2OG concentration. Reaction mixture
includes, Thr387àAla, (0.3 μM), (NH4)2Fe(SO4)2 (10 μM), ascorbic acid (1 mM), 2OG
(1-1000 µM), and CODD (10 μM) in 50 mM HEPES pH 7.00, 37°C, ambient [O2](217
μM).
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Figure 3.3 Determination of steady state kinetic constants kcat /KM(2OG) for WT-PHD2
and Thr387àAsn. Graph A is WT-PHD2 and graph B is Thr387àAsn. Reaction mixture
includes, WT-PHD2 or Thr387àAsn, (1 µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1
mM), 2OG (1-3000 µM), and CODD (10 µM) in 50 mM HEPES pH 7.00, 37°C, ambient
[O2](217 µM).

Table 3.1 Steady state kinetics of WT-PHD2 and mutants with varied [2OG].
Enzyme

kcat

kcat/KM

KI(2OG)

KM(2OG),

KD(2OG)

min-1

µM-1min-1

µM

µM

µM

WT-PHD2

2.3 ± 0.1

2.7 ± 0.4

>2.6x104

0.9 ± 0.2

0.7 ± 0.2

Thr387àAla

32.9 ± 1.4

2.7 ± 0.3

2150 ± 338

12.0 ± 1.6

1.2 ± 0.2

Thr387àAsn

1.0 ± 0.1

1.5 ± 0.2

>5x104

0.7 ± 0.1

0.6 ± 0.2

3.3.2 Binding constants for 2OG
Intrinsic tryptophan fluorescence was monitored upon binding 2OG to determine
the binding constant for the PHD2 + 2OG ⇔ PHD2/2OG equilibrium. WT-PHD2 and
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Thr387àAla were excited at 295 nm and the emission was monitored at 330 m upon
titration with 2OG then the data were fitted to the equation 3 (Figure S1). Each enzyme
bound 2OG with similar affinity, as shown by the KD for WT-PHD2 (0.8 µM),
Thr387àAla (1,2 µM) and Thr387àAsn (0.6 µM) had a (Table 3.1), indicating that
mutation of Thr387 did not significantly alter the binding of 2OG.

Figure 3.4 Determination of KD(2OG) for WT-PHD2, Thr387àAla and Thr387àAsn
upon intrinsic fluorescence quenching of tryptophan upon binding of 2OG to the enzyme
active site. Closed circles WT-PHD2 (1.1 µM), open circles Thr387àAla (1 µM ),
triangles Thr387àAsn (1.1 µM), each with MnSO4 (20 µM) in 50 mM HEPES pH 7.00
titrated with 2OG (500 µM).
	
  
3.3.3 Steady state kinetics with varied [CODD]
The initial rates of CODD hydroxylation were measured as a function of varied
CODD concentration for WT-PHD2 and the point mutants ain 50 mM HEPES (pH 7.00,
37°C), with saturating concentrations of Fe2+ (1 µM), 2OG (100 µM), and ascorbate (1
mM); the [O2] was fixed at ambient conditions (217 mM nominally). Steady state
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constants, kcat, and kcat/KM(CODD), were determined by fitting the data to the MichaelisMenten equation. The rate constants for WT-PHD2 at saturating [CODD] was kcat = 1.9
min-1, and kcat/KM(CODD) = 2.4 µM-1min-1), were in good agreement with prior
reports18,23,26. The conservative Thr387àAsn mutant exhibited rate constants (kcat 0.9
min-1, kcat/KM= 0.7 µM-1min-1) that were modestly decreased from those of WT-PHD2,
suggesting that Thr387àAsn mutation did not alter hydrogen bonding within the active
site (Figure 3.5). In contrast, the Thr387àAla mutant exhibited initial rates that were
much faster than those of WT-PHD2, as well as pronounced inhibition at elevated CODD
concentrations (Figure 3.6).
The initial rate data for Thr387àAla was fitted in two ways in order to adequately
treat the inhibition. The first fitting attempted used the Michaelis-Menten equation to fit
the initial rate data from 0 – 10 µM, leading to fitted parameters of kcat = 32.5 min-1 and
kcat/KM = 13 µM-1min-1. These kinetic constants were remarkable because they indicated
that removing the hydrogen bonding group from position 387 led to an enzyme that was
15 times more reactive than WT-PHD2, suggesting that WT-PHD2 was not fully
optimized for maximal turnover frequency. The very high kcat value for this mutant
indicated that the rate-limiting step became faster as compared to WT-PHD2 – this step is
likely decarboxylation of 2OG for WT-PHD2.

However, this fit was not good, as

indicated by the systematic derivation between the fitted curve and the data. and
succinate release for Thr387àAla (see discussion). The second fitting attempted used the
substrate inhibition model and resulted in kcat = 44 min-1, kcat/KM = 11 µM-1min-1, and KI
= 39 µM (Table 3.2). This second fit reproduced the data well, revealing that the peptide
substrate (CODD) inhibited Thr387àAla rather strongly.
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Figure 3.5 Determination of kinetic constants kcat/KM(CODD) for WT-PHD2 and
Thr387àAsn. Triangles WT-PHD2 and circles are Thr87àAsn. Reactions include, WTPHD2 (1 µM) or Thr387àAsn (2 µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1 mM),
2OG (100 µM), and CODD (2-40 µM) in 50 mM HEPES pH 7.00, 37°C, ambient
[O2](217 µM).

Figure 3.6 Substrate inhibition for Thr387àAla at high CODD concentration. Reaction
mixture included Thr387àAla (0.2 µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1 mM),
2OG (100 µM), and CODD (2-50 µM) in 50 mM HEPES pH 7.00, 37°C, ambient
[O2](217 µM). Insert is the steady state kinetics between 2 µM to 50 µM CODD.
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Table 3.2 Steady state kinetic constants, kcat and kcat/KM of WT-PHD2, Thr387→Ala and
Thr387→Asn for CODD substrate peptide.	
  
	
  
Enzyme
kcat ,min-1 kcat/KM(CODD), µM-1min-1
KI, µM
KM, µM
WT-PHD2

1.9 ± 0.1

2.4 ± 0.2

-

0.8 ± 0.1

Thr387→Ala

44.4 ± 3.3

10.8 ± 1

38.4 ± 6.4

4.1 ± 0.7

Thr387→Asn

0.9 ± 0.1

0.7 ± 0.1

-

1.4 ± 0.2

3.3.4 Kinetic SIE on kcat
Solvent isotope effects (SIEs) are unique measurements that reveal the ratelimitation of steps associated with proton motion or with the release of aquo ligands from
metal ions35. As aquo release is a curicial step preceding O2 activation in the 2OG
oxygenases KSIEs can reveal whether an early step or a late step is rate limiting on kcat.
In the case of WT-PHD2, an inverse kinetic SIE was observed on kcat ((SIE)kcat = 0.75),
indicating that an irreversible step after aquo release was partially rate-limiting on kcat18.
The kinetic SIE was measured in 50 mM HEPES buffer pH/pD = 7.00 for WTPHD2 and the point mutants. (SIE)kcat was inverse for both WT-PHD2 (0.75) and for
Thr387àAsn (0.81), which indicated a pre-equilibrium aquo release immediately
preceded the rate-limiting step (Figure 3.7 panel A)35. In contrast, the kinetic SIE for
Thr387àAla was normal ((SIE)kcat = 2.92), which indicated that proton transfer was ratelimiting on kcat for this mutant (Figure 3.7 panel B)35.
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Figure 3.7 Solvent isotope effect on WT-PHD2, Thr387àAla, and Thr387àAsn. WTPHD2 in D2O buffer (▲), WT-PHD2 in H2O buffer (Δ); Thr387àAsn in D2O buffer (■),
Thr387àAsn in H2O (☐). Thr387àAla in D2O buffer (●); H2O buffer (○). Reactions
include, WT-PHD2 (1 µM), Thr387àAla (1 µM), or Thr387àAsn (0.3 µM),
(NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1 mM), 2OG (100 µM), and CODD (10 µM) in
50 mM HEPES pH 7.00 or pD 7.00, 37°C, ambient [O2](217 µM).
	
  
Table 3.3 SIE kinetic parameters for PHD2 and its variants.
Enzyme

H

WT-PHD2

1.9 ± 0.1

2.6 ± 0.2

0.8

Thr387àAla

32.5 ± 2.5

11.1 ± 0.2

2.9

Thr387àAsn

0.9 ± 0.1

1.1 ± 0.1

0.8

	
  

kcat ,min-1

D

kcat, min-1
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SIE(kcat)

3.3.5 Steady state kinetics with varied [O2]
The initial rates were measured as a function of varied O2 concentration using
saturating concentration of Fe2+ (10 µM), 2OG (100 µM), ascorbic acid (1 mM), and
CODD (10 µM). The initial rate data for WT-PHD2 and Thr387àAsn showed simple
saturation kinetics over the range of 6 µM to 1 mM O2 concentration and was fitted to the
michealis-menten equation, KM(O2) (527.33 µM, 757.01 µM) and kcat/KM(O2) (0.015 µM1

min-1, 0.05 µM-1min-1) (Figure 3.8). Thr387àAla mutant exhibited normal saturation

kinetics between 6 µM to 217 µM O2 range, with the kinetic parameters of KM(O2) (102
µM) and kcat/KM(O2) (0.3 µM-1min-1) (Figure 3.9). But interestingly Thr387àAla inhibited
at higher than 217 µM O2 concentration. Fitting the initial rate data to an inhibition
model led to kinetic parameters of kcat (401 min-1), kcat/KM(0.35 µM-1min-1) and KI(11
µM) (Table 3.4).

Figure 3.8 Steady state kinetics constants kcat(O2) and kcat/KM(O2) for WT-PHD2 and
Thr387àAsn. Reaction mixture includes, WT-PHD2 (1 µM) or Thr387àAsn (2 µM),
(NH4)2Fe(SO4)2 (10 µM), 2OG (100 µM), CODD (10 µM), and ascorbic acid (1 mM) in
50 mM HEPES pH 7.00. Open circles are WT-PHD2 and the closed circles are
Thr387àAsn.
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Figure 3.9 Steady state kinetics constants kcat (O2) and kcat/KM (O2) for Thr387àAla.
Reaction mixture includes, Thr387àAla (0.2 µM), (NH4)2Fe(SO4)2 (10 µM), 2OG (100
µM), CODD (10 µM), and ascorbic acid (1 mM) in 50 mM HEPES pH 7.00. Insert,
steady state kinetics of Thr387àAla between 6 µM to 760 µM O2.
	
  
	
  
Table 3.4 Steady state kinetics constants kcat(O2) and kcat/KM(O2) for WT-PHD2,
Thr387àAla, and Thr387àAsn.
Enzyme

kcat ,min-1

kcat/KM, µM-1min-1

KM, µM

KI, µM

WT-PHD2 (1)

8 ± 0.7

0.015 ± 0.001

530 ± 90

-

Thr387→Ala (1)

28.3 ± 2.6

0.3 ± 0.1

102 ± 22

-

Thr387→Ala (2)

401 ± 14

0.4 ± 0.1

1136.9 ± 158

11 ± 00

Thr387→Asn (1)

3.8 ± 0.5

0.005 ± 0.001

757.03 ± 168

-

(1) is fit equation 1 and (2) is fit for equation 2.
[Fe2+] = 10 µM, [2OG] = 100 µM, [CODD] = 10 µM, 37 oC, pH 7.00.
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3.3.6 Inhibition by added succinate
	
   Effects of succinate on WT-PHD2 and Thr387àAla activity tested at varied [2OG].
Activity assays performed with ascorbic acid (1 mM), (NH4)2Fe(SO4)2 (10 µM), 2OG (2100 µM), and succinate (0 – 1 mM) in an air saturated 50 mM HEPES pH 7.00 at 37 OC.
Initial rates were obtained as described earlier and KI(Succinate) obtained by plotting the
initial rate vs [2OG] for each [Succinate] and data fitted to competitive inhibition
equation (equation 3) using global fitting setting in Origin. WT-PHD2 and Thr387àAla
had different KI(Succinate), 490 µM and 260 µM, respectively.

Figure 3.10 Inhibition of WT-PHD2 and Thr387àAla. Upper panel is WT-PHD2 and the
lower panel is Thr387àAla. Reaction includes, ascorbic acid (1 mM), (NH4)2Fe(SO4)2
(10 µM), PHD2 (0.15-1 µM), 2OG (2-100 µM) and succinic acid (0-1 mM) in an air
saturated 50 mM HEPES pH 7.00 at 37 oC.
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Table 3.5 WT-PHD2 and Thr387àAla KI(Succinate).
Enzyme

kcat, min-1

KI(Succinate), µM

WT-PHD2

2.7 ± 0.3

491 ± 74

Thr387àAla

33.2 ± 0.5

261 ± 50

3.4

Discussion
Mutation of Thr387 to remove the second-sphere hydrogen bond to the coordinated

aquo ligand led to significant changes in the kinetic constants and inhibition patterns of
PHD2. These changes in observed parameters arise due to a change in rate-limiting step
for the Thr387àAla mutation, which unmasks product release in this mutant.

This

implicates the hydrogen bond from Thr387 in impeding the ability of O2 to react at the
Fe(II) center, and points to this residue as being a key component in the mechanical
linkage that stimulates hydroxylation in PHD2 once HIF-1α-ODD binds.
Thr387àAla alters the rate-limiting step(s).
The Thr387àAla mutation changes the rate-limiting step on kcat for PHD2, from a
step involved with O2 binding/activation in WT-PHD2 to product release step. The
observation of increased kcat for Thr387àAla is unusual, as point mutations typically
attenuate catalytic power in enzymes. That this mutation leads to an increased kcat
indicates that one or more microscopic steps have increased in rate. The simplest way to
increase kcat for this mutant would be to increase the rate of the rate-limiting step for WTPHD2, which is most likely a step associated with O2 binding/activation.

That O2

binding/activation is rate-limiting for WT-PHD2 relies on the observation of an inverse
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SKIE on kcat (Dkcat = 0.8)18, indicating that the rate-limiting step is an irreversible step
after aquo release, and the absence of any oxidized intermediate in the pre-steady state,
Bollinger which indicates that HAT/rebound are fast. The observation of a large, normal
SKIE for Thr387àAla (D2Okcat = 2.9) excludes this possibility for the mutant, and is most
consistent with a product release step as rate-limiting on kcat.
A simple model that accounts for the normal SKIE and the substrate inhibition
found for Thr387àAla is one in which either succinate release becomes slow in this point
mutant, such that the (Fe+succ)PHD2 form of enzyme would accumulate in the steady
state. Inhibition by 2OG or by CODD would arise from these substrates binding to the
enzyme, thereby preventing the enzyme from adopting the proper cofactor orientation to
enter into catalysis. This is in contrast to WT-PHD2, for which a step prior to HAT is
likely

rate-limiting

meaning

that

the

accumulating

enzyme

form

is

(Fe+2OG+CODD)PHD2 – WT-PHD2 does not experience substrate inhibition because a
second molecule of 2OG or CODD cannot bind to this enzyme form.
Binding of CODD peptide to (Fe+succ)PHD2 simply requires that the enzyme
can adopt a closed conformation22,27,28, but binding of 2OG to this form of enzyme would
require that both succinate and 2OG simultaneously bind to the cofactor. Precedent for
the Fe(II) cofactor binding two carboxylic acids comes from the 2OG-substrate inhibition
observed from histone demethylases21. We note that an alternate possibility is that CO2
release is the slow step for Thr387àAla. Although CO2 release is typically indicated as
preceding hydroxylation in the consensus mechanism, an intriguing possibility is that
CO2 release from Fe occurs through hydrolysis, to form carbonic acid directly – but this
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is simple speculation. In either case, the binding of 2OG or CODD to an enzyme/product
form would impede turnover in Thr387àAla.
Thr387àAla increases O2 reactivity
Comparison of the steady-state rate constants reveals that removing the hydrogen
bond from Thr387 specifically increases the rate of step(s) associated with O2 activation.
As understanding how substrate binding stimulates O2 activation is crucial to figuring out
how the HIF hydroxylases respond to changes in pO2, we focused our attention on kinetic
constants reporting on O2 activation.

Only those kinetic constants reporting on O2

activation increased in magnitude for the Thr387àAla mutant relative to WT-PHD2,
indicating that removal of this hydrogen bond accelerated O2 activation. This in turn
suggests that the indirect hydrogen bond from Thr387 is a central piece of the mechanical
linkage that stimulates O2 activation only after CODD binds.
As the second-order rate constant (kcat/KM(O2)) report on steps between binding of
O2 and the subsequent irreversible step, inspection of a kinetic mechanism for PHD2
shows that that these steps consist of reversible O2 binding (k5, k6) and oxidative
decarboxylation (k7). Our experimental conditions used saturating levels of 2OG and
CODD, such that our reported values for kcat/KM(O2) are isolated on these steps. Both
WT-PHD2 and the conservative Thr387àAsn mutant exhibit rather sluggish reactivity
toward O2, with kcat/KM(O2) = 0.015 µM-1min-1 (~ 0.25 x 10-9 M-1 sec-1), consistent with
prior reports29,30 The Thr387àAla mutant is a contrast to this, as kcat/KM(O2) = 0.3 µM-1
min-1, a 20-fold increase in reaction rate which indicates that step(s) involving O2
activation have markedly increased in rate for this point mutant. The increased kcat and
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kcat/KM(CTAD) observed for Thr387àAla further point to acceleration of oxidative
decarboxylation in this mutant over that observed for WT-PHD2.
The inactivation of Thr387àAla at elevated [O2] further suggests that oxidative
decarboxylation is much faster in this mutant than in WT-PHD2 (Figure 3.9). We
attempted to fit this inactivation profile to a model in which O2 acted as an inhibitor, but
could not obtain a satisfactory fit to the model. A second possibility, that of succinate
inhibition, was tested (Figure 3.10) but similar inhibition constants were observed for
both WT-PHD2 (KI(Succinate) = 491 µM) and Thr387àAla (261 µM). We propose that
this inactivation arises from auto-oxidation or an internal auto-hydroxylation of a PHD2
residue, as is seen for several other 2OG oxygenases31–34.
Implications for substrate-stimulating hydroxylation
The acceleration in the O2-activation rate for Thr387àAla suggest that this mutant
has perturbed the chemical mechanism of PHD2 in such a way that O2-activation is
accelerate the Thr387àAla mutant implies that this hydrogen bond is a key component of
the mechanical linkage leading to hydroxylation chemistry.

Scheme 3.2 Steps in the chemical mechanism of Thr387àAla showing the
inhibition mechanism by 2OG.
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Scheme 3.3 Steps in the chemical mechanism of Thr387àAla showing the
inhibition mechanism by CODD.
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CHAPTER IV

PHD2 HAS A Zn(II) BINDING ALLOSTERIC SITE
4.1

Introduction
The cellular response to the challenge of low pO2 (hypoxia) is curial to tissue

development, with the transcriptional level of hundreds of genes controlled by HIF-1α
controlled genes include those associated with balancing aerobic an anaerobic
metabolism, as well as angiogenesis and erythropoiesis1–3.

A small group of four

oxygenase enzymes regulate the activity of HIF-1α, with the HIF-prolyl hydroxylase 2
(PHD2) viewed as the primary cellular oxygen sensor in humans4–6. PHD2 hdroxylates
Pro402 and Pro564 within the N- and C- terminal oxygen degradation domain of HIF-1α,
leading to the proteasomal degradation of HIF-1α7–9. Consequently, PHD2 and the other
HIF hydroxylases are therapeutic targets for diseases such as cancer and ischemia10,11.

PHD2 is a member of a superfamily of 2OG dependent non heme Fe(II)
dioxygenase (2OG oxygenases) that hydroxylates carbon rich substrates via oxidative
decarboxylation of 2OG1,5,12,13. The balanced reaction for PHD2 is: O2 + 2OG + Pro
→ CO2 + succinate + Pro-OH in which Pro = Pro402 and Pro564. As for other members
of this superfamily, the Fe(II) cofactor in resting enzyme in bound by a 2HisAsp facial
triad (His313, His374, and Asp315), a bidentate 2OG, and a labile ligand that s typically
H2O. PHD2 is unusual as it binds Fe(II) tightly (KM ~ 0.03 µM)14, in constant to other
members of this superfamily (KD ~ 1-10 µM)15,16.
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A number of metals and 2OG-mimics are known to inhibit the 2OG oxygenases,
including PHD217,18,19–21. The active site of 2OG oxyganses tolerate the later transition
metals as evidenced by in vitro and in vivo experiments18,22. X-ray crystal structures
containing Mn2+, Zn2+, Co2+, as well as the other spectroscopic studies of 2OG oxyganses
constituted with Cu2+ and Co2+, demonstrate that the active site of 2OG oxyganeses can
be constituted with numerous metals. PHD2 is no exception, with structures containing
Mn2+ and Zn2+ has been crystalized23–25. Similarly, a wide variety of chelates displace
2OG in vitro, as shown by enzyme inhibitor screens. Furthermore elevated levels of
metabolic intermediates, such as succinate and alpha-hydroxyglutarate, can displace 2OG
under conditions of over abundance and impact the activity of 2OG oxygenases,
including PHD2.

The literature contains conflicting data regarding the in vivo and in vitro inhibition of
2OG oxygenase by metal ions. In vitro assays generally show that d-block metals bind to
the active site of 2OG oxygenases with KD ~10 µM, however PHD2 is a notable
exception14,15. In vivo metal displacement at histone and nucleotide demethylases has
been proposed o lead to a number of epigenetic changes, with active site binding metals
shown in vitro

18

. Although Co2+, metal chelators, and DMOG are commonly used to

induce hypoxia sensitive gene expression within cell culture, recent reports suggest that
various HIF hydroxylases are differentially inhibited by these agents in the cells14. The
mechanism of enzyme inhibition has ben attributed to competition with Fe2+ for the
active site, ascorbic acid depletion, or effects remote from the active site.
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PHD2 is particularly confounding, as the apparent inhibitory effects of different
metal ions depend greatly on sample history, and the presence of a second site for metal
binding. Purified PHD2 retains significant activity and Fe2+ content due to the tight
binding of Fe2+, which leads samples of PHD2 to contain variable metal unless the metal
is specifically removed by extended treatment with EDTA. The IC50 for d-block metals
toward purified PHD218,22 was significantly lower than toward crude PHD2 suggesting
that leaching of Fe2+ from the active site during purification made PHD2 more
susceptible to exogenous metals. Similarly, PHD2 exhibits only partial inhibition with
certain metals, and purified PHD2 was shown to bind two metal ions under certain
conditions; one at the active site and the other at a surface site requiring Cys201

26

.

Consequently, the inhibition noted for PHD2 may simply depend on whether the species
present at the time of metal competition is (Fe)PHD2, (Fe + 2OG)PHD2, or apo PHD2,
as well as whether or not the surface site can be accessed.
Regulating enzyme activity through allosteric binding site is a strategy used for
many important cellular processes, particularly those necessary for adopting to alter
growth conditions. Hypoxia is an existential challenge for higher organisms, as complex
tissues experience varied levels of pO2 under normal conditions, with even more complex
gradients of pO2 under the challenge of disease or toxicity. The centrality of hypoxia
sensing to development responses makes understanding those factors impacting hypoxia
sensitive gene expression crucial for health and disease.
The surface metal binding site is intriguing, due to the MYND in full length
PHD2. In this work coordination of the surface site have been identified as Cys201,
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Cys208, Tyr197, His205, and two water ligands. Metal inhibition assays suggest that this
this site can possibly be targeted for control the enzyme activity.

Figure 4.1 A) Allosteric site showing the Zn2+ binding residues, H2O (red sphere) PDB
ID: 2G19. B) PHD2 active site showing the Fe2+ and coordinating residues, H2O (red
sphere) PDB ID: 3OUJ.
	
  
4.2

Experimental procedures

4.2.1 Materials
All the chemicals were purchased from chemical vendors, and used without
further purification.

The ODD peptide was DLDLEALAP564YIPADDDFQL. The

underlined residues were changed from the native sequences as follows: M561A, M568A
to avoid methionine oxidation and was purchased from GL Biochem LTD (Shanghai) (99
%

purity).

For

Cys201àAla

mutation

GTGCTTGTTCATGGCCGGCACGATGTACTCGAGC-3`

primers,

5`-

and

5`-

GCTCGAGTACATCGTGCCGGCCATGAAGCAC-3` has been used (IDT).
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4.2.2 Protein expression and purification
The recombinant WT-PHD2 and Cys201àAla mutant were expressed in E. coli
BL21(DE3) cells using a pGEX-4T-1 vector (Stratagene) with an N-terminal GST tag.
The GST-PHD2 fusion protein was purified using an affinity column (GSTrap, GE
Bioscience), then the GST tag was removed by incubating in restriction grade thrombin
(1 unit thrombin/ mg PHD2) for 16 hours at 4 oC. Following thrombin removal using a
Hitrap Benzamidine column (GE Bioscience), GST-tag was removed by GSTrap column.
Purified PHD2 was incubated with 50 mM EDTA overnight at 4 oC, then buffer
exchanged with 50 mM HEPES 150 mM NaCl pH 7.50 for storage at -20 oC.
4.2.3 Initial rate measurements
PHD2 and Cys201àAla activities were determined by direct measurement of the
hydroxylation of Pro564 residue in 19 residue fragment of ODD domain using Bruker
Daltinics Omniflex MALDI-TOF mass spectrometer. Initial rates (ν0) were obtained
from change in mol fraction of hydroxylated ODDOH (χODDOH) equation 4.1
Equation 4.1 𝜐!   = [𝑂𝐷𝐷]! 𝜒!""!# /𝑡
For steady state kinetic assays, all the saturating concentrations of reagents were
used. Reaction mixture includes, PHD2 (1 µM), 2OG (100 µM), (NH4)2Fe(SO4)2 (10
µM), M(SO4) (50 µM), ascorbic acid (1 mM) and ODD (20 µM).
4.2.4 Metal inhibition assays
All the activity assays were performed with PHD2 (1 µM) and saturating
concentrations of ascorbic acid (1 mM), 2OG (100 µM), and (NH4)2Fe(SO4)2 (10 µM) in
50 mM HEPES pH 7.00 at 37 oC. In metal competition assays 10 µM (NH4)2Fe(SO4)2
and varying concentrations of M(SO4) (M, Zn, Co, Mn, Ni, Cu) from 5 µM to 200 µM
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were used. In one set of experiments (NH4)2Fe(SO4)2 and M(SO4) were added to PHD2
at the same time and incubated with the enzyme for 3 minutes.

After 3 minutes

incubation of PHD2 with the two metals, the reaction was initiated by addition of 20 µM
ODD. Aliquots were quenched with 2:1 ratio of acetonitrile and 0.2 % trifluoroacetic
acid saturated with 4-α-cyanohydroxycinnamic acid at different time points (20 second to
3 minutes).

In a second set of experiment the enzyme pre-incubated with 10 µM

(NH4)2Fe(SO4)2 100 µM 2OG, and 1 mM ascorbic acid for 3 minutes. After 3 minutes
incubation reaction second metal (MSO4) was added and the reaction mixture incubated
additional 3 more minutes then the reaction was initiated by adding 20 µM ODD.
4.2.5 X-ray Absorption Spectroscopy Sample Preparation
XAS samples were prepared by mixing PHD2 (1 mM) with 1 mM
(NH4)2Fe(SO4)2 and 1mM 2OG in an air saturate buffer (50 mM HEPES 150 mM NaCl
pH 7.50) for 15 minutes on ice. Samples were then treated with chelex for 30 minutes to
remove unbound Fe2+ from samples. After treatment removal with chelex, chelex
removed by centrifuging the samples and removing the sample with a pipette. Then 0.9
mM of ZnSO4 or NiSO4 was added to the PHD2 samples, which were incubated on ice
10 more minutes. Each sample was loaded to XAS sample holder and immediately
frozen in liquid N2.
4.3

Results

4.3.1 PHD2/Cys201àAla has different inhibition profile with different addition
order of metals
When WT-PHD2 was incubated with Fe2+ and divalent transition metals, Zn2+, Mn2+,
Co2+, Cu2+, or Ni2+, each lead to a strong inhibition of WT-PHD2 except NiSO4, which
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partially inhibited the enzyme by only 20 % (Figure 4.1 panel A). The inhibitory effects
of 10 µM metal followed the trend Cu>Zn>Co,Mn>>Ni, which is consistent with the
Irving William series with the exception of Ni. Pre incubation of WT-PHD2 with Fe2+
mostly prevented the inhibition of enzyme by retaining the activity of WT-PHD2 up to
65-80 % at 200 µM metal concentration, except for Cu2+, which lead to a strong
inhibition (Figure 4.1 panel B).

The inhibition profile in Figure 4.2 suggested that inhibition was allosteric. Since
a previous study showed that two metal ions can be bind to PHD2 and that mutation of
Cys201 to Ala prevented the binding of two transition metals26, we purified the
Cys201àAla mutant and tested it for metal inhibition. Under competitive assay
conditions, each of the late 3d metals inhibited the Cys201àAla mutant similarly to WTPHD2. When Cys201àAla was pre incubated with Fe2+ then tested with metals, overall
inhibition trend was very similar to that observed for WT-PHD2, with only Cu2+
inhibiting the enzyme by more than 50 % (Figure 4.2 panel B).

Inhibition profile where the WT-PHD2 pre incubated with Zn2+, Co2+, Mn2+, and
Ni2+ and increasing concentration of Fe2+ (from 10 µM to 200 µM) added, shows that
Fe2+ can not displace these metal from active site except for the Ni2+. Increasing [Fe2+]
up to 200 µM enzyme gained its activity by 30 % (Figure 4.3).

	
  

83	
  

Figure 4.2 Inhibition of WT-PHD2 from concentration of 10-200 µM M2+ (M2+ = Mn2+,
Co2+, Ni2+, Cu2+, Zn2+). Panel A, the metals were added at the same time with cofactor
Fe2+ and co-substrate 2OG. Panel B, second metal MSO4 added after pre incubated WTPHD2 with Fe2+. Reactions performed with WT-PHD2 (1 µM), 2OG (100 µM),
(NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1mM), M(SO4) (0-200 µM) and ODD (20 µM)
in 50 mM HEPES pH 7.00 at 37 oC.
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Figure 4.3 Inhibition of Cys201àAla from concentration of 10-200 µM M2+ (M2+ =
Mn2+, Co2+, Ni2+, Cu2+, Zn2+). Panel A, the metals were added at the same time with
cofactor Fe2+ and co-substrate 2OG. Panel B, second metal MSO4 added after pre
incubated the Cys201àAla with Fe2+. Reactions performed with WT-PHD2 (1 µM), 2OG
(100 µM), (NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1mM), M(SO4) (0-200 µM) and
CODD (10 µM) in 50 mM HEPES pH 7.00 at 37 oC.
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Figure 4.4 Inhibition of WT-PHD2 by Mn2+, Co2+, Ni2+, and Zn2+ when PHD2 pre
incubated with one of these metals then increasing [Fe2+] from 10 µM to 200 µM.
Reactions performed with WT-PHD2 (1 µM), 2OG (100 µM), MSO4 (10 µM), ascorbic
acid (1mM), (NH4)2Fe(SO4)2 (0-200 µM) and CODD (20 µM) in 50 mM HEPES pH 7.00
at 37 oC.
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Figure 4.5 inhibition of WT-PHD2 by Mn , Co2+, Ni2+, and Zn2+ when (Fe2+)PHD2
incubated with one of these metals for three hours. Reactions performed with WT-PHD2
(1 µM), 2OG (100 µM), MSO4 (50 µM), ascorbic acid (1mM), (NH4)2Fe(SO4)2 (10 µM)
and CODD (20 µM) in 50 mM HEPES pH 7.00 at 37 oC.
2+
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4.3.2 Addition of second metal does not change KM(CODD) except for the Co2+, and
Zn2+.
Saturating concentrations of Fe2+(10 µM), 2OG (100 µM), ascorbic acid (1 mM)
and 50 µM test metal used as this was saturated for the inhibition curves and ODD varied
to test for inhibition of E and ES form of the enzyme. Steady state kinetic measurements
indicate that addition of test metal to PHD2 led to modest inhibition of kcat but more
pronounced effect on kcat/KM(CODD) (Table 4.1). To the predominant enzyme form under
conditions of saturating [ODD] is the ES form, this is indicates that the added metals
modestly slowed the ES →→ E + P conversion. In contract free E dominates under
saturating [ODD], and kcat/KM(CODD) effects on the E + S ⇔ ES → EP steps. As these
steps were slowed markedly (M = Zn2+ and Co2+) its is likely that Co2+ and Zn2+ altered
PHD2’s affinity to substrate ODD by 2 to 3 fold, possibly due to a conformational
change.
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Figure 4.6 Steady state kinetics for WT-PHD2 pre incubation with Fe2+ (10 µM), 2OG
(100 µM) and 50 µM M2+ (Mn2+, Co2+, Ni2+, or Zn2+). Reactions were performed, 1 µM
WT-PHD2 pre incubated with Fe2+ (10 µM), 2OG (100 µM), ascorbic acid (1 mM), M2+
(50 µM) and ODD (2-20 µM) in 50 mM HEPES pH 7.00 at 37 oC.

Table 4.1 Steady state kinetic constants in the presence of 50 µM Mn2+, Co2+, Ni2+, or
Zn2+ for WT-PHD2 pre incubated with Fe2+ (10 µM), 2OG (100 µM), ascorbic acid (1
mM).
Enzyme
(10Fe)PHD2

	
  

kcat (min-1)
1.9 ± 0.1

kcat/KM (µM-1min-1)
2.5 ± 0.2

KM (µM)

0.8 ± 0.1

(10Fe)PHD2(50Ni)

1.7 ± 0.1

1.7 ± 0.1

1.0 ± 0.1

(10Fe)PHD2(50Mn)

1.7 ± 0.1

1.7 ± 0.2

1.0 ± 0.1

(10Fe)PHD2(50Zn)

1.4 ± 0.1

0.8 ± 0.1

1.7 ± 0.2

(10Fe)PHD2(50Co)

1.6 ± 0.1 0.5 ± 0.1
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3.4 ± 0.2

4.3.3 XAS shows that Zn2+ binds to the allosteric site on WT-PHD2
The allosteric metal binding site was happen to be centered with Cys201 by
mutagenesis. We wished to define the metical parameters of this site using EXAFS. Xray absorption spectroscopy shows that Zn2+ binds to the allosteric site of PHD2,
adopting a six coordinate geometry, two cysteine (Cys201 and Cys208), one Tyr197, His205
and two water ligand. In the case of Cys201àAla, Zn2+ bound to the active site, which
was replacing the Fe3+. In aerobic samples of WT-PHD2 and Cys201àAla with Fe3+ and
Ni2+, Ni2+ expelled the Fe3+ from the active site and bound to the active site.

Figure 4.7 K-edge XAS spectra of WT-PHD2 with Zn(II) (Done by Carolyn Carr)
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Figure 4.8 K-edge XAS spectra of Cys201àAla with Zn2+ (Done by Carolyn Carr)
Table 4.2 Selected EXAFS fits for WT-PHD2 and Cys201àAla with Zn2+ and Fe3+
(Done by Carolyn Carr)
Sample

CN

Shell

r (Å)

σ2 (x10-3 Å-2) ΔEo (eV)

%R

WT Zn(II)

6

3N/O

2.07(2)

2.6(1.8)

2.9(0.9)

0.57

2S

2.32(1)

5.5(1.0)

1Br

2.39(2)

12.8(3.3)

4N/O

2.10(1)

2.3(0.6)

1.4(0.8)

1.6

1N/O

2.22(1)

3.89(0.7)

1Br

2.44(2)

12.7(2.1)

(1Imd)

2.07(2)

2.6(1.8)

2.9(0.9)

0.57

(1Imd)
(1Tyr)

C201A Zn(II)

6

(2Imd)
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4.4

Discussion
There was a conflict about how certain transition metals such as, Zn2+, Ni2+, Co2+,

Cu2+, and Mn2+ induce hypoxic response and stabilize HIF-1α. The most likely reason is
due to the inhibition of PHD2, which is responsible in regulating HIF-1α level in the
cells.

Two possible way of PHD2 inhibition by these metals has been proposed

previously. First one is these transition metals simply replace the Fe2+ from the active
site which requires tighter binding of these metals than Fe2+ to enzyme active site.
Second one, these transition metals bind to different place on enzyme rather that the
active site and allostericly inhibits the PHD2.
Our addition of order experiments revealed that Zn2+, Cu2+, Mn2+ and Co2+
preferably binds to the active site instead of Fe2+ under competitive conditions. Except
with the Ni2+, which showed only 25 % inhibition which suggest that active site has
higher preference for Fe2+ than Ni2+. Under noncompetitive conditions where the enzyme
pre-incubated with Fe2+ then the second metal was added, enzyme showed a different
inhibition profile in case of Zn2+, Mn2+, and Co2+ these metals inhibited the enzyme by
only 40 % suggesting that these metals are not replacing the Fe2+ instead inhibiting the
enzyme a different way, possibly allostericly. Exception with the Cu2+ which completely
inhibited enzyme like competitive conditions, by binding to enzyme active site and Ni2+
also inhibited the enzyme by 25 % similar inhibition profile with competitive conditions.
Since there has been a report showing that PHD2 can bind more that one metal
such as Zn2+, Co2+ and Cu2+ and mutation of either of Cys201àAla and Cys208àAla
prevented binging of two metal and only one metal binds to these mutants indicated that
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these metals binding to these Cys201Cys208 site (scoff). We performed Cys201àAla
mutation to investigate how is the inhibition profile would be when we removed the
second metal binding site. Our competitive and noncompetitive activity measurements
with these metals had the similar inhibition profile with WT-PHD2, which suggest that
either these metals can still bind to the Cys201Cys208 site even though we removed one
ligand or this second site is not effecting the enzyme activity.
Our XAS experiments indicated that Zn2+ binds to the Cys201Cys208 allosteric site
in aerobic samples with six coordinate, Cys201, Cys208, Tyr197, His205, and two water
ligands. Based on the crystal structure His205 residue appears to be bit far, this indicates
that in order for Zn2+ bind PHD2 goes to conformational change. Aerobic Cys201àAla
Zn2+ sample seems like binds to the active site rather than the allosteric site, one possible
reason for this is Zn2+ can replace the Fe3+ from the active site when Cys201 ligand is
removed or during the chelex treatment chelex might have pull out the Fe3+ from the
active site.
Involvement of HIF-1α on disease such as angiogenesis, erythropoiesis, tumor
growth, and etc. makes the PHD2 a potential drug target for hypoxia related diseases.
Problem with the targeting the enzyme active site cause problems, biggest problem is
same family of enzymes share common active site and it makes it difficult to come out
with highly specific compound. Therefore, it is more convenient to control the enzyme
activity away from the active site to obtain greater selectivity. This research is valuable
to showing that it is possible to control the PHD2 activity away from the active site.
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CHAPTER V

SECOND COORDINATION SPHERE CONTROLS HIF-1α HYDROXYLATION
5.1

Introduction
HIF prolyl hydroxylase (PHD2) is a human O2 sensor. It is a non-heme Fe2+ 2-

oxoglutarate (2OG) dependent dioxygenase, which controls the level of hypoxia
inducible factor-1α (HIF-1α) in cells1–3. HIF-1α is a transcription factor, which transactivates the expression of over 100 genes such as angiogenesis, erythropoiesis, tumor
growth, and etc., so its abundance in the body is important4–7. PHD2 controls HIF-1α
level by hydroxylating two specific proline residues in the ODD domain of HIF-1α,
Pro402 and Pro564 1,8–10. Hydroxylation of one or both proline residues is enough for HIF1α to be recognized by pVHL, a part of E3 ubiqutin ligase, which targets HIF-1α for
proteasomal degradation1,11–13. The role of PHD2 in controlling HIF-1α level makes it
essential to understand how these enzyme work and which residues are essential for its
hydroxylating function.
PHD2’s Fe2+ active site is six coordinate with a two histidine (His313 and His374) one
aspartate (Asp315) facial triad (2His1Asp), co-substrate 2OG bound in a bidentate manner
and a water ligand, these ligands are called first coordination sphere. PHD2 follows a
sequential ordered binding mechanism. First substrate ODD binds and displaces a water
ligand which opens up a coordination for O2 binding, O2 binds to this open coordination
site upon O2 activation, co-substrate 2OG gets decarboxylated and the substrate gets
hydroxylated14–18 (scheme 5.1). The first coordination sphere residues are significant for
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enzymatic reactivity but also the second coordination sphere residues may also play an
important role.

Scheme 5.1 Proposed chemical mechanism for PHD2
Crystal structures of PHD219 indicates that PHD2 has an extended hydrogen bonding
network with second coordination sphere residues, which possibly play an important role
in enzyme activity. Residue Thr325 is involved in an hydrogen bonding with the facial
triad Asp315 residue. This hydrogen bonding might be important for proper positioning of
Asp315, in order for chemistry to occur. Here we tested the role of Thr325 residue in
positioning the Asp315, facial triad residue by performing point mutations, steady state
kinetic experiments and UV-Vis spectroscopy.
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Our results revealed that Thr325 residue plays an important role in enzyme
activity.

Thr325àAla mutation was 5 times less reactive in hydroxylating CODD

substrate compared to WT-PHD2. We also replaced the Asp315 ligand with glutamate,
which is very similar to aspartate only one carbon bond longer. The Asp315àGlu mutant
had the same activity with WT-PHD2 and Asp315àAla mutation was very slow
compared to wild type enzyme but it still hydroxylated CODD peptide. The same
mutations in other 2OG dependent dioxygenase, FIH, was reported to inhibit the
enzyme20 unlike PHD2. Reactivity of Asp315àAla mutant hydroxylating CODD shows
that Fe2+ can still bind to the active site with two histidine ligands. This research shows
that there is more flexibility of in the Fe2+ coordination environment than other 2OG
dependent dioxygenases.

Figure 5.1 Active site of PHD2 showing the 2His1Asp facial triad, 2OG and Thr325
residue. PDB ID: 3OUJ, distances (Å) and Water (red sphere).
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5.2

Materials and methods

5.2.1 Materials
All the chemicals were purchased from chemical vendors, and used without
further purification. 20 residue CODD substrate peptide (99 % purity) was purchased
from GL Biochem LTD (Shanghai). The primers used were: Thr325àAla, forward, 5’	
   –
CCA	
  AAT	
  GGA	
  GAT	
  GGA	
  AGA	
  TGT	
  GTG	
  GCA	
  TGT	
  ATA	
  TAT	
  TAT	
  CTT	
  AAT	
  AAA	
  GA-‐3’;	
  
reverse,	
  5’-‐	
  TCT	
  TTA	
  TTA	
  AGA	
  TAA	
  TAT	
  ATA	
  CAT	
  GCC	
  ACA	
  CAT	
  CTT	
  CCA	
  TCT	
  CCA	
  
TTT	
   GG	
   -‐3’;	
   Asp315àAla, forward,	
   5’-‐	
   GGG	
   TTA	
   TGT	
   ACG	
   TCA	
   TGT	
   TGC	
   TAA	
   TCC	
   AAA	
  
–	
   3’;	
   reverse,	
   5’-‐	
   TTC	
   CAT	
   CTC	
   CAT	
   TTG	
   GAT	
   TAG	
   CAA	
   CAT	
   GAC-‐3’;	
   Asp315àGlu,
forward, 5’- GTT ATG TAC GTC ATG TTG AGA ATC CAA ATG-3’; reverse,	
  5’-‐	
  TTC	
  
CAT	
   CTC	
   CAT	
   TTG	
   GAT	
   TCT	
   CAA	
   CAT	
   GAC-‐3’.	
   	
   The	
   primers	
   were	
   purchased	
   from	
  
IDT.	
  
5.2.2 Point mutations
Point mutations were performed by using the protocole modified from the
quickchange site-directed mutagenesis kit of Stratagene.

Mutation primers were

designed for Asp315àAla, Asp315àGlu, and Thr325àAla mutants by using the
quickchange primer design program of Stratagene. At least 30 basepaire legth primers
were used and the mutated base was at the center of the primer sequence. Reactions
prepared for the PCR are shown on table 5.1.
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Table 5.1 PCR reaction conditions.
Reagent

Stock concentration

Volume used

ddH2O

84 µL

10X reaction buffer

10 µL

dNTP

1 µL

MgSO4

Final amount

100 mM

1 µL

1 mM

Primer (Sense)

125 ng/µL

1 µL

125 ng

Primer (Anti-sense)

125 ng/µL

1 µL

125 ng

pGEX-4T

100 ng/µL

1µL

100 ng

Vent polymerase

1 µL

Table 5.2 The PCR program setting.
Step

Temperature (OC)

Time

Denaturing

95

50 seconds

Denaturing

95

50 seconds

Annealing

62-65

50 second

Extension

72

7 minutes

Extension

72

7 minutes

Store

4

Bold, 16 cycles performed.
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The PCR reactions were loaded to 1% agarose gel to check the plasmid replication.
After the PCR product was confirmed on the agarose gel, samples were treated with DpnI
for 1 hour at 37 OC to remove parental plasmid from PCR products. Then 5 µL of DpnI
treated PCR products were transformed to XL-1 blue cells and plated onto Ampicillin LB
agar plates. Plates were incubated at 37 OC for overnight. A single colony was picked
and grown in 5 mL of LB media containing Ampicillin media at 37 OC for overnight. A
miniprep was performed to isolate the plasmid from the overnight culture. To confirm
the sequence of the plasmids, sequencing samples were prepared containing 50 ng of
plasmid and one of the sequencing primer either primer #29 or primer#35 then sent for
sequencing. Plasmids with mutated sequence were then transformed into BL-21 DE3
cells, using the same procedure for XL-1 blue cell transformation.
5.2.3 Purification of WT-PHD2 and its mutants, Asp315àAla, Asp315àGlu, and
Thr325àAla
WT-PHD2 and its mutant variants were purified as previously described21,22. In
summary, WT-PHD2 and its mutants were expressed in E. coli BL-21 DE3 cells using a
pGEX-4T-1 vector (stratagene) as N-terminally GST-tag fusion protein. GST-PHD2
fusion protein was purified using a GSTrap affinity column (GE Bioscience), then the
GST tag cleaved by treating the sample with restriction grade thrombin at 1 unit/mg at 4
O

C for 16 hrs. After 16 hours incubation with thrombin, the thrombin was removed using

Hitrap Benzamidine column (GE Bioscience), then the GST tag removed by a GSTrap
column. Purity of enzymes were checked with 10 % SDS page and the masses were
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confirmed by QStarTOF mass spectrometer. Purified WT-PHD2 and its variants were
then buffer exchanged with 50 mM HEPES pH 7.5 and storred at -20 OC.
5.2.4 Steady state kinetic assays
Steady state kinetic assays were performed under saturating concentrations of
(NH4)2Fe(SO4)2 (10 µM), 2OG (100 µM), CODD (10-20 µM), ascorbic acid (1 mM), and
enzyme (1-2 µM). Initial rates were determined by directly measuring the hydroxylation
of CODD peptide by Bruker Daltinics Omniflex MALDI-TOF mass spectrometer. Initial
rates (v0) were obtained from the change in mol fraction of hydroxylated CODDOH 2
(cODDOH), as v0 = [CODD]0 cODDOH /t.
5.2.5 Buffer preparation to obtain pH profile
A three component buffers was prepared for pH range from 6.00 to 7.50 using 20
mM HEPES, 20 mM MES, and 20 mM PIPES. For pH 8.00 60 mM HEPES buffer was
prepared and for pH 8.5 to pH 10.00 60 mM CHES buffers were prepared. Reactions
were performed with each pH. The pH of the reaction was also measured using a micro
pH meter.
5.2.6 Steady state kinetics for determining KM(O2)
The initial rate measurements were performed under saturating concentrations of
Fe2+ (10 µM), 2OG (100 µM), and ascorbic acid (1 mM) in 50 mM HEPES pH 7.00 at 37
o

C. O2 concentration was varied by continuously flowing the N2 and O2 gas at different

ratios through a bag, then O2 concentration monitored by YSI model 5300 biological
oxygen monitor. Reactions were quenched at different time points in matrix solution,
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saturated 4-α-cyano hydroxycinnamic acid (in 75 % acetonitrile and 0.2 %TFA).
Samples were then spotted onto a target plate and analyzed by a Bruker Daltonics
Omniflex MALDI-TOF mass spectrometer.
5.2.7 UV-Vis spectroscopy
Anearobic samples of WT-PHD2, its variants, 2OG, Fe2+, 50 mM HEPES pH 7.00
were prepared by flushing argon gas through the samples for 30 minutes. The samples
were then taken into a glove box in which the UV-Vis samples were prepared. Samples
contained WT-PHD2 or its mutant (600 µM), 2OG (600 µM), and Fe2+ (550 µM) in 50
mM HEPES pH 7.00 buffer containing 150 mM NaCl . Apo WT-PHD2 and apo mutant
spectrum also obtained and used as background spectrum.
5.3

Results

5.3.1 Thr325àAla plays a key role in hydroxylating the CODD substrate peptide
The initial rates of turnover were measured as a function of varied CODD or
2OG, and the rate constants, KM and kcat/KM were obtained by fitting the data to a
Micheles-menten equation (equation 5.1). Steady state kinetic assays showed that
KM(CODD) and KM(2OG) were similar to the wild type PHD2 for all the mutants (Table 5.3)
while kcat/KM were different for Thr325àAla and Asp315àAla. Thr325àAla form of the
PHD2 had 5 times less reactivity for hydroxylating CODD than WT-PHD2. Since the
Asp315 is one of the active site facial triad residues, breaking it drastically inhibited the
enzyme.

The Asp315àGlu mutant had similar activity with WT-PHD2, which was

interesting because previously, a similar mutation to an enzyme of the same class of
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enzymes had been reported to inhibit that enzyme but for PHD2 this small alteration in
the active site residue did not change its activity.

Figure 5.2 Determination of kinetic constants kcat/KM(CODD) for WT-PHD2, Asp315àAla,
Asp315àGlu, and Thr325àAla. Closed squares are WT-PHD2, open triangles are
Asp315àAla, closed triangles are Asp315àGlu, and open circles are Thr325àAla.
Reactions include, WT-PHD2 (1 µM) or mutant (2-10 µM), (NH4)2Fe(SO4)2 (10 µM),
ascorbic acid (1 mM), 2OG (100 µM), and CODD (2-20 µM) in 50 mM HEPES pH 7.00,
37°C, ambient [O2](217 µM).
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Figure 5.3 Determination of kinetic constants kcat/KM(2OG) for WT-PHD2 and,
Asp315àAla, Asp315àGlu, and Thr325àAla. Closed squares are WT-PHD2, open
triangles are Asp315àAla, closed triangles are Asp315àGlu, and open circles are
Thr325àAla.
Reactions include, WT-PHD2 (1 µM) or mutant (2-10 µM),
(NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1 mM), 2OG (1-50 µM), and CODD (20 µM) in
50 mM HEPES pH 7.00, 37°C, ambient [O2](217 µM).
	
  
Table 5.3 Steady state kinetic parameters of WT-HD2 and mutants for CODD and 2OG.
Enzyme

kcat, min-1

kcat/KM, min-1

KM(CODD), µM

KM(2OG), µM

µM-1
WT-PHD2

2.7 ± 0.1

3.9 ± 0.5

0.7 ± 0.1

1.2 ± 0.2

Thr325àAla

0.4 ± 0.1

0.2 ± 0.1

1.5 ± 0.2

1.6 ± 0.3

Asp315àAla

0.04 ± 0.01

0.6 ± 0.1

0.1<

0.06 ± 0.03

Asp315àGlu

2.1 ± 0.1

3.0 ± 0.4

0.7 ± 0.1

3.3 ± 0.4
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5.3.2 Mutations did not alter the protonation state of PHD2
PHD2 activity as previously reported is highly pH dependent. The pKa of WTPHD2 and its mutants were determined by measuring the initial rate turnover of substrate
CODD in the pH range of 6-9.5. All the initial rate measurements were performed under
saturating concentrations of (NH4)2Fe(SO4)2 (10 µM), 2OG (100 µM), ascorbic acid (1
mM), CODD (20 µM), and WT-PHD2 (1 µM) or mutant (2-10 µM) in an air saturated
HMP (HEPES + MES + PIPES) or CHES buffer at 37°C. The initial rates of turnover
were measured as a function of varied [CODD]. pKas were determined for WT-PHD2
and its mutants by fitting the data to equation 5.2. The rate of turnover for WT-PHD2 was
pH dependent as previously reported. At pH 6.75, WT-PHD2 had its highest activity,
which indicates the PHD2 has an active site acid and upon deprotonation , the enzyme
showed lower activity. All of the mutants also showed similar pH dependence and they
had very similar pKas (Table 5.4) suggesting that none of these mutated residues are the
cause of PHD2’s pH dependence.
!

!!

!"#$  
!"#$  
Equation 5.3 𝑓 𝑠 =    𝑘!!"# +    !!!"
(!"! !!)
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Figure 5.4 pKa of WT-PHD2 and its mutants. Closed squares are WT-PHD2, open
triangles are Asp315àAla, closed triangles are Asp315àGlu, and open circles are
Thr325àAla.
Reactions include, WT-PHD2 (1 µM) or mutant (2-10 µM),
(NH4)2Fe(SO4)2 (10 µM), ascorbic acid (1 mM), 2OG (100 µM), and CODD (20 µM) in
HMP (HEPES + MES + PIPES) or CHES buffer at ambient [O2], 37 °C.

Table 5.4 pKa of WT-PHD2 and its mutants.

	
  

Enzyme

pKa

WT-PHD2

7.6 ± 0.1

Thr325àAla

7.9 ± 0.1

Asp315àAla

7.5 ± 0.1

Asp315àGlu

7.5 ± 0.2
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5.3.3 WT-PHD2 and mutants have similar KM(O2) exception the Asp315àGlu mutant
which showed inhibition at high [O2]
The initial rates of WT-PHD2, Asp315àAla, Asp315àGlu, and Thr325àAla were
measured at a varied O2 concentrations using the saturating concentrations of Fe2+ (10
µM), 2OG (100 µM), and ascorbic acid (1 mM) in 50 mM HEPES pH 7.00 at 37 °C. WTPHD2 and mutants showed simple saturation kinetics over the range of 6 µM to 1 mM O2
concentration except Asp315àGlu which showed inhibition at higher than 600 µM [O2],
(Figure 5.5). The steady state kinetic parameters of the mutants were similar to that of
WT-PHD2 (Table 5.5) with the exception of Asp315àGlu which had a lower KM(O2), than
WT-PHD2, 207 µM and 576 µM respectively (Table 5.5). These results indicate that
Thr325 and Asp315 do not play a role in the affinity of the enzyme for O2.
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Figure 5.5 Determination of kinetic constants kcat/KM(O2) for WT-PHD2, Asp315àAla,
Asp315àGlu, and Thr325àAla. Closed squares are WT-PHD2, open triangles are
Asp315àAla, closed triangles are Asp315àGlu, and open circles are Thr325àAla.
Reactions include, WT-PHD2 (1 µM) or mutant (2-10 µM), (NH4)2Fe(SO4)2 (10 µM),
ascorbic acid (1 mM), 2OG (100 µM), and CODD (20 µM) in 50 mM HEPES pH 7.00,
37 °C.

Table 5.5 Steady state kinetic parameters of WT-PHD2 and mutants for O2.

	
  

Enzyme

kcat/KM(O2), min-1 µM-1

KM(O2), µM

WT-PHD2

0.02 ± 0.01

527 ± 92

Thr325àAla

0.003 ± 0.001

486 ± 171

Asp315àAla

0.01<

576 ± 124

Asp315àGlu

0.02 ± 0.01

207 ± 45
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5.3.4 Electron density around the Fe2+ has been altered in Asp315àAla and
Asp315àGlu mutants
Previous reports with PHD2 and other dioxygenase such as FIH, taurine dioxygenase
(TauD) showed that changes in the Fe2+ coordination environment lead to shifts in the
UV-visible absorption spectra in the 300 - 600 nm range due to the metal to ligand charge
transfer transitions (MLCT)16,17,21,23. In this case the MLCT is between Fe2+ and 2OG cosubstrate. UV-visible absorption spectra of anaerobic samples of (Fe2+ + 2OG + WTPHD2) and its mutant variants (Fe2+ + 2OG + Mutant) were recorded to monitor any
possible changes to the Fe2+ coordination environment. Apo WT-PHD2 and apo mutant
spectrums were also obtained and used as background spectra.

MLCT region has

changed in the Asp315àGlu and Asp315àAla mutants. As seen in figure 5.6, it shifted
from 500 nm to 490 nm.
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Figure 5.6 The UV-visible spectrum of WT-PHD2, Asp315àGlu, and Asp315àAla with
Fe2+ 2OG. (Fe2+ + 2OG)WT-PHD2, (Fe2+ + 2OG)Asp315àGlu, and (Fe2+ + 2OG)
Asp315àAla. Black line is (Fe2+ + 2OG)WT-PHD2, sample includes 600 µM WTPHD2, 550 µM Fe2+ and 600 µM 2OG. Dark gray line is (Fe2+ + 2OG)Asp315àGlu,
sample includes 600 µM Asp315àGlu, 550 µM Fe2+, and 600 µM 2OG. Light gray line is
(Fe2+ + 2OG)Asp315àAla, samples includes, 350 µM Asp315àGlu, 320 µM Fe2+, and
350 µM 2OG in 50 mM HEPES 150 mM NaCl pH 7.00.
	
  
5.4

Discussion
Our steady state kinetic experiments indicated that second coordination sphere

residue Thr325 is essential for positioning the Asp315 facial triad residue and breaking the
hydrogen bonding between these two residues inhibited the enzyme by 80 %.
Interestingly, the KM(CODD), KM(2OG), and KM(O2) are not altered by alanine (Table 5.3)
suggesting that Thr325 is not involved in CODD, 2OG or O2 binding. Previous reports
showed that PHD2’s activity is highly pH dependent and the enzyme is more reactive in
hydroxylatingg CODD at lower pH.

	
  

Our pH experiments results indicate that
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Thr325àAla mutation did not altered the protonation state of PHD2 and Thr325 is not
responsible for the pH dependence of PHD2.

Facial triad residues (2His1Asp) are highly conserved among the non-heme Fe2+
dependent dioxygenases and removal of one of these ligands was reported to inhibit the
enzymatic activity in other dioxygenases such as FIH.

We performed mutation of

Asp315àAla and Asp315àGlu and tested the hydroxylation activity and our results
revealed that Asp315àGlu mutation can hydroxylate the CODD peptide as effective as
WT-PHD2 with the apparent kcat/KM of 3.0 and 3.9, respectively (Table 5.3).

The

Asp315àAla mutant had very low reactivity for hydroxylating CODD. Both mutants of
Asp315 had similar pKa values to WT-PHD2, indicating that Asp315 does not play a role in
pH dependence of PHD2. Asp315àAla’s ability to hydroxylate CODD substrate peptide
indicates that Fe2+ can bind to the active site even without one of the ligands or highly
conserved 2His1Asp facial triad ligands.

We also tested the O2 sensitivity of Asp315àAla and Asp315àGlu compared to the
WT-PHD2. Asp315àAla had a similar KM(O2) to WT-PHD2, 576 µM and 527 µM,
respectively (Figure5.5), while Asp315àGlu mutant showed different kinetic behavior
compared to WT-PHD2. WT-PHD2 activity increased with increasing [O2] and had
maximum activity higher than 800 µM whereas Asp315àGlu mutant’s activity increased
with increasing [O2] concentration until 600 µM [O2] then activity started to drop at
higher [O2] (Figure 5.5). In some 2OG dependent dioxygenases such as FIH it has been
reported that the enzyme can auto hydroxylate itself forming an inactive or less reactive
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form of the enzyme. The inhibition of Asp315àGlu with increasing [O2] suggest that
Asp315àGlu might also be doing auto hydroxylation like FIH does which leads to partial
enzyme inhibition at higher than 600 µM [O2].

The UV-visible spectroscopy showed that the electron density around the Fe2+ active
site center of WT-PHD2 has changed with Asp315àGlu and Asp315àAla mutants. The
blue shift in MLCT band was observed with these mutations (Figure 5.6). For WTPHD2 and Thr325àAsn mutant MLCT bands appeared at 500 nm while for Asp315àGlu
and Asp315àAla mutant, it appeared at 490 mM. Similar shifts in MLCT bands have
been previously reported for FIH23.

This study showed that Thr325 residue plays an important role in CODD hydroxylation
by positioning the Asp315 residue for effective hydroxylation as removal of the interaction
between these two residues causes partial enzyme inhibition. The replacement of Asp315
with alanine or glutamate do not prevent binding of Fe2+ to the active site based on
activity assays but it binds more weakly to Asp315àAla as seen by UV-vis studies
(Figure 5.6) and unlike some other non-heme Fe2+ 2OG dependent dioxygenases20 PHD2
does not lose its ability to hydroxylate CODD substrate peptide.
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5.5

Bibliography

1.

Berra, E. et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low
steady-state levels of HIF-1alpha in normoxia. The EMBO journal 22, 4082–90
(2003).

2.

Aprelikova, O. et al. Regulation of HIF prolyl hydroxylases by hypoxia-inducible
factors. Journal of cellular biochemistry 92, 491–501 (2004).

3.

Bruick, R. K. & McKnight, S. L. A conserved family of prolyl-4-hydroxylases that
modify HIF. Science (New York, N.Y.) 294, 1337–40 (2001).

4.

Iyer, N. V. et al. Cellular and developmental control of O2 homeostasis by
hypoxia-inducible factor 1alpha. Genes & Development 12, 149–162 (1998).

5.

Huang, L. E., Gu, J., Schau, M. & Bunn, H. F. Regulation of hypoxia-inducible
factor 1alpha is mediated by an O2-dependent degradation domain via the
ubiquitin-proteasome pathway. Proceedings of the National Academy of Sciences
of the United States of America 95, 7987–92 (1998).

6.

Forsythe, J. a et al. Activation of vascular endothelial growth factor gene
transcription by hypoxia-inducible factor 1. Molecular and cellular biology 16,
4604–13 (1996).

7.

Wang, G. L., Jiang, B. H., Rue, E. a & Semenza, G. L. Hypoxia-inducible factor 1
is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension.
Proceedings of the National Academy of Sciences of the United States of America
92, 5510–4 (1995).

8.

Bruick, R. K. & McKnight, S. L. A conserved family of prolyl-4-hydroxylases that
modify HIF. Science (New York, N.Y.) 294, 1337–40 (2001).

9.

Appelhoff, R. J. et al. Differential function of the prolyl hydroxylases PHD1,
PHD2, and PHD3 in the regulation of hypoxia-inducible factor. The Journal of
biological chemistry 279, 38458–65 (2004).

10.

Semenza, G. L. Hydroxylation of HIF-1: oxygen sensing at the molecular level.
Physiology (Bethesda, Md.) 19, 176–82 (2004).

11.

Ivan, M. et al. HIFalpha targeted for VHL-mediated destruction by proline
hydroxylation: implications for O2 sensing. Science (New York, N.Y.) 292, 464–8
(2001).

	
  

114	
  

12.

Jaakkola, P. et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation
complex by O2-regulated prolyl hydroxylation. Science (New York, N.Y.) 292,
468–72 (2001).

13.

Masson, N., Willam, C., Maxwell, P. H., Pugh, C. W. & Ratcliffe, P. J.
Independent function of two destruction domains in hypoxia-inducible factor-alpha
chains activated by prolyl hydroxylation. The EMBO journal 20, 5197–206 (2001).

14.

Zhou, J. et al. Substrate Binding to the r -Ketoglutarate-Dependent Non-Heme Iron
Enzyme Clavaminate Synthase 2  : Coupling Mechanism of Oxidative
Decarboxylation and Hydroxylation. 13539–13540 (1998).

15.

Hausinger, R. P. FeII/alpha-ketoglutarate-dependent hydroxylases and related
enzymes. Critical reviews in biochemistry and molecular biology 39, 21–68
(2004).

16.

Hoffart, L. M., Barr, E. W., Guyer, R. B., Bollinger, J. M. & Krebs, C. Direct
spectroscopic detection of a C-H-cleaving high-spin Fe(IV) complex in a prolyl-4hydroxylase. Proceedings of the National Academy of Sciences of the United
States of America 103, 14738–43 (2006).

17.

Price, J. C., Barr, E. W., Tirupati, B., Bollinger, J. M. & Krebs, C. The first direct
characterization of a high-valent iron intermediate in the reaction of an alphaketoglutarate-dependent dioxygenase: a high-spin FeIV complex in taurine/alphaketoglutarate dioxygenase (TauD) from Escherichia coli. Biochemistry 42, 7497–
508 (2003).

18.

Grzyska, P. K. et al. Steady-state and transient kinetic analyses of taurine/alphaketoglutarate dioxygenase: effects of oxygen concentration, alternative sulfonates,
and active-site variants on the FeIV-oxo intermediate. Biochemistry 44, 3845–55
(2005).

19.

McDonough, M. a et al. Cellular oxygen sensing: Crystal structure of hypoxiainducible factor prolyl hydroxylase (PHD2). Proceedings of the National Academy
of Sciences of the United States of America 103, 9814–9 (2006).

20.

Lando, D. et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the
transcriptional activity of hypoxia-inducible factor. Genes & development 16,
1466–71 (2002).

21.

Flagg, S. C., Giri, N., Pektas, S., Maroney, M. J. & Knapp, M. J. Inverse solvent
isotope effects demonstrate slow aquo release from hypoxia inducible factor-prolyl
hydroxylase (PHD2). Biochemistry 51, 6654–66 (2012).

	
  

115	
  

22.

Pektas, S. & Knapp, M. J. Substrate preference of the HIF-prolyl hydroxylase-2
(PHD2) and substrate-induced conformational change. Journal of inorganic
biochemistry 126, 55–60 (2013).

23.

Saban, E., Flagg, S. C. & Knapp, M. J. Uncoupled O2-activation in the human
HIF-asparaginyl hydroxylase, FIH, does not produce reactive oxygen species.
Journal of inorganic biochemistry 105, 630–6 (2011).

	
  

	
  

116	
  

CHAPTER VI

FUTURE DIRECTIONS
1. Today there is no intermediate observed for PHD2 but very interesting kinetic
behavior of Thr387àAla mutant now can make it possible. Our steady state kinetic
studies with Thr387àAla mutation indicated that release of succinate is RDS and using
Stopped-flow instrument it may be possible the monitor Fe(IV)-(Succinate) complex or
even some other intermediates.

2. Our results revealed that PHD2 has six coordinate Zn(II) binding site and its
role in regulating PHD2 activity still needs to be studied. Binding of two metal to PHD2
in the case of Cu(II) and Co(II) was also reported previously, these metals are possibly
binding to these Cys201Cys208 site and the effect of these metals on PHD2 activity need
further study.
	
  
3. According to a consensus chemical mechanism substrate binding to the active
site happens prior to oxygen activation. Based on the crystal structure of PHD2
containing a 17 residue fragment of the CODD, it is witnessed that the substrate induces a
large conformational change in the structure of PHD2. The loop region (β2β3) flips up
and closes over the active site entrance (Figure 6.1).
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Figure 6.1 A) PHD2 crystal structure without substrate (2G19). B) PHD2 crystal
structure with the substrate (colored purple) (3HQR). (Both structures have the same
orientation).
	
  
Although there is no clear way for O2 to reach the active site there appears to be a
convoluted channel. Residues, Gln239, Arg252, Trp258, Ile256, and Met299 residues of PHD2
and Tyr565 residue in ODD line the front of the proposed oxygen channel (Figure 6.1).
My model is if this cavity is necessary for O2 to enter the active site then the enzyme
activity can be altered by changing the width of the channel. If convoluted channel is O2
channel then it might be possible to make the PHD2 active at lower [O2] by altering the
size of these channel by point mutations.
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Figure 6.2 A view of O2 channel, showing the residues line in front of the channel.
Purple stick representation is CODD.
	
  
In order to test whether it is an O2 channel or not, point mutations of residues
(Figure 6.2), Gln239àAla, Arg252àAla, Trp258àAla, Ile256àA, and Met299àAla in
PHD2 and another mutation in CODD, Tyr565àAla which increase the size of this cavity
can be performed. KM(O2) values for each mutant can be determined and compared to wild
type enzyme. If this possible channel is necessary for O2 to enter the PHD2 active site, it
is expected that those alanine mutations will increase the rate of O2 entering the active
site, which will decrease the KM(O2). It is possible that PHD2 can do the hydroxylation
chemistry at lower [O2].
Crystallographic Studies of Xe binding experiment can be done to visualize the
O2 channel. Xe binds to hydrophobic surface in the proteins Xe will pass from this O2
channel and bind to the active site. The binding rate for each mutant expected to be
higher than the wild type of the enzyme.
The results gained from these experiments will be vitally important to control the O2
access structurally.
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APPENDIX A

pGEX-4T-1 VECTOR (FROM GE HEALTHCARE)
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APPENDIX B

AMINO ACID SEQUENCE OF WT-PHD2178-426 THAT WAS USED IN THIS
STUDY
	
  

178

GSRPNGQTKPLPALKLALEYIVPCMNKHGICVVDDFLG

KETGQQIGDEVRALHDTGKFTDGQLVSQKSDSSKDIRGD
KITWIEGKEPGCETIGLLMSSMDDLIRHCNGKLGSYKING
RTKAMVACYPGNGTGYVRHVDNPNGDGRCVTCIYYLNK
DWDAKVSGGILRIFPEGKAQFADIEPKFDRLLFFWSDRRN
PHEVQPAYATRYAITVWYFDADERARAKVKYLTGEKGVR
V E L N K P S D S V G K D V F426
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APPENDIX C

FORWARD AND REVERSE PRIMER SEQUENCES OF MUTANTS
	
  
Thr387àAla, forward, 5’- CAT ATG CTA CAA GGT ACG CAA TAG CTG TTT -3’;
reverse, 5’- GCA TCA AAA TAC CAA ACA GCT ATT GCG TA -3’.
Thr387àAsn, forward, 5’- CCA	
  GCA	
  TAT	
  GCT	
  ACA	
  AGG	
  TAC	
  GCA	
  ATA	
  AAT	
  GTT	
  TGG	
  
TAT	
  TTT	
  GAT	
  -‐3’;	
  reverse,	
  5’-‐	
  ATC	
  AAA	
  ATA	
  CCA	
  AAC	
  ATT	
  TAT	
  TGC	
  GTA	
  CCT	
  TGT	
  
AGC	
  ATA	
  TGC	
  TGG	
  -‐3’.	
  
Cys201àAla, forward, 5’- GCT	
  CGA	
  GTA	
  CAT	
  CGT	
  GCC	
  GGC	
  CAT	
  GAA	
  CAA	
  GCA	
  C	
  -‐3’;	
  
reverse,	
  5’-‐	
  GTG	
  CTT	
  GTT	
  CAT	
  GGC	
  CGG	
  CAC	
  GAT	
  GTA	
  CTC	
  GAG	
  C	
  -‐3’.
Thr325àAla, forward, 5’	
  –CCA	
  AAT	
  GGA	
  GAT	
  GGA	
  AGA	
  TGT	
  GTG	
  GCA	
  TGT	
  ATA	
  TAT	
  
TAT	
   CTT	
   AAT	
   AAA	
   GA	
   -‐3’;	
   reverse,	
   5’-‐	
   TCT	
   TTA	
   TTA	
   AGA	
   TAA	
   TAT	
   ATA	
   CAT	
   GCC	
  
ACA	
  CAT	
  CTT	
  CCA	
  TCT	
  CCA	
  TTT	
  GG	
  -‐3’.	
  
Asp315àAla, forward,	
  5’-‐	
  GGG	
  TTA	
  TGT	
  ACG	
  TCA	
  TGT	
  TGC	
  TAA	
  TCC	
  AAA	
  -‐3’;	
  reverse,	
  
5’-‐	
  TTC	
  CAT	
  CTC	
  CAT	
  TTG	
  GAT	
  TAG	
  CAA	
  CAT	
  GAC	
  -‐3’.	
  
Asp315àGlu, forward, 5’- GTT ATG TAC GTC ATG TTG AGA ATC CAA ATG-3’;
reverse,	
  5’-‐	
  TTC	
  CAT	
  CTC	
  CAT	
  TTG	
  GAT	
  TCT	
  CAA	
  CAT	
  GAC-‐3’.	
  
Sequencing	
   primers,	
   forward	
   (#29),	
   5’-‐	
   CAT	
   GGA	
   CCC	
   AAT	
   GTG	
   CCT	
   GGA	
   TG-‐3’;	
  
reverse(#35),	
  5’-‐	
  CTC	
  CGC	
  TAT	
  CGC	
  TAC	
  GTG	
  ACT	
  G-‐3’.	
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